Synthesis and properties of iso-bicyclo DNA

Anna-Barbara Gerber and Christian J. Leumann*[a]

Abstract: We present the synthesis of the iso-bicyclo DNA building blocks with the nucleobases A, C, G and T, as well as biophysical and biological properties of oligonucleotides derived thereof. The synthesis of the sugar part was achieved in 5 steps starting from a known intermediate of the tricyclo-DNA synthesis. Dodecamers containing single iso-bicyclo thymidine incorporations, fully modified A- and T-containing sequences and fully

modified oligonucleotides containing all four bases were synthesized and characterized. Iso-bicyclo DNA forms stable duplexes with natural nucleic acids with a pronounced preference for DNA over RNA as complements. The most stable duplexes, however, arise by self-pairing. Iso-bicyclo DNA forms preferentially B-DNA-like duplexes with DNA and A-like duplexes with complementary RNA as determined by CD-spectroscopy. Self-paired duplexes

show a yet unknown structure, as judged from CD-spectroscopy. Biochemical tests revealed that iso-bicyclo DNA is stable in fetal bovine serum and does not elicit RNase H activity.

Keywords: oligonucleotides • nucleosides • bicyclo-DNA • serum stability • RNase H

Introduction

Oligonucleotides are a class of compounds with considerable therapeutic potential. Unlike small molecule drugs that typically target proteins, therapeutic oligonucleotides act via Watson-Crick hybridization to a matched sequence tract on an RNA of interest, modulating its biological function.^[1] Originally, mRNAs of disease related proteins have been the target of classical antisense oligonucleotides that either sterically block or induce RNase H degradation of the mRNA *in vivo*.^[2] The project ENCODE,^[3] recently revealed that 80% of the human genome is transcribed into RNA. Of these RNAs only 2% encode for proteins while a considerable subset, such as micro-RNAs (miRNAs) and generally non-coding RNAs, is involved in gene regulation. Thus, they play a pivotal role in the onset of disease which greatly expands the palette of RNA sequences as therapeutic targets in the future.

Basic requirements for therapeutic oligonucleotides are i) high affinity towards a target RNA, ii) biostability, and iii) cellular availability. A large number of chemical modifications on the DNA bases, sugar and internucleoside linkage have been reported over the last two decades, but only a handful of those have been used in extensive pre-clinical or clinical tests. Amongst those are the class

of 2'-O-alkylated RNA,^[4] the morpholino phosphorodiamidates,^[5] the peptide nucleic acids (PNA)^[6] and the locked nucleic acids (LNA)^[7].

In our laboratory we have been involved in the design and synthesis of conformationally constrained oligonucleotides over the last two decades. Offsprings of these efforts were the bicyclo-^[8] and tricyclo-DNA^[9] molecular platform (Figure 1). Unique to both families is the carbocyclic 5-membered ring connecting C(5') and C(3') and thereby rigidifying the rotational freedom around the C(3')-C(4') and the C(4')-C(5') bonds (Figure 1, A and C).

Besides conformational restriction this carbocyclic ring offers the unique advantage to change the geometry of the repeating backbone unit in a single strand by moving the hydroxyl groups involved in the internucleotidic linkages to other C-atoms within the cycle. In this context we became interested in exploring the properties of iso-bicyclo-DNA (Figure 1 B) in which the the C(5') hydroxyl group has been moved to C(6'). Interestingly, this iso-bicyclo-DNA shows the same number of bonds within the repeating backbone unit as DNA. In this article we report on the synthesis of the corresponding iso-bicyclo-DNA building blocks with all four natural bases, on their incorporation into oligonucleotides, their RNA and DNA recognition properties, as well as on their structure as determined by CD-spectroscopy and their biological properties (serum stability and RNaseH activation).

Figure 1. A: bicyclo DNA, B: iso-bicyclo DNA, C: tricyclo DNA

[a] Dr. A.-B. Gerber, Prof. C. J. Leumann
Department of Chemistry & Biochemistry
University of Bern
Freiestrasse 3, 3012 Bern (Switzerland)
Fax: (+41)31-631-3422
E-mail: leumann@ioc.unibe.ch

Results

Molecular modeling of monomers: To investigate the influence of the C(5') → C(6') hydroxyl shift on the structure of the nucleosides a conformational search was performed using the MM+ force field as implemented in the software package HyperChem™. The C(3'), C(5') dimethylated iso-bicyclo thymidine was initially built in a 2'-endo conformation and then energy minimized. In a conformational search experiment all endocyclic torsion angles were then varied, resulting in two different low energy conformational families (Figure 2). Table 1 summarizes the endocyclic torsion angles of the furanose unit and the corresponding energies of two representative structures of each family. The lowest energy conformer turned out to be that with the 6' substituent in an axial position (Figure 2a). This structure fits well into a B-DNA double helix as judged from simple model building.

Figure 2. Lowest energy conformers of 3',5'-dimethylated iso-bicyclo-thymidine: a) O(6') in axial position, furanose in C(1')-exo conformation; b) O(6') in equatorial position, furanose in C(4')-exo conformation.

Table 1. Results of the conformational search experiment for an iso-bicyclic thymidine. ω is the angle between the phosphate oxygen and the C6'

	v0	v1	v2	v3	v4	ω	Furanose pucker	Energy [kcal/mol]
a)	-41°	35°	-17°	-6°	30°	82°	C(1')-exo	29.22
b)	-36°	15°	8°	-30°	41°	170°	C(4')-exo	30.26

Synthesis of the iso-bicyclo sugar: The bicyclic silyl enolethers **1a** (C(1') α), **1b** (C(1') β) used in the synthesis of the tricyclo sugar^[10] were considered to be the starting materials of choice for the synthesis of the iso-bicyclo DNA scaffold. Hydroboration of **1a** or **1b** yielded the compounds **2a**, **2b** and **3a**, **3b** (Scheme 1) in diastereomeric ratios of 4:1 in the α -series and 10:1 in the β -series.^[11] The lowest abundant isomer **3b** could not be isolated as a pure compound and was not used in further transformations. All other isomers **2a**, **2b** and **3a** were taken forward in the following nucleoside synthesis. Acetylation of **2a**, **2b** and **3a** was performed under standard conditions using Ac₂O/DMAP in pyridine at room temperature yielding **4a**, **4b** and **5a**. Desilylation with HF/Et₃N (37% HF) in THF yielded compounds **6a**, **6b** and **7a**. To defunctionalize C(5'), the alcohols **6a**, **6b** and **7a** were converted into the thiocarbamates **8a**, **8b** and **9a** in good yields. The subsequent Barton McCombie

Scheme 1. a) 1. BH₃·THF, THF, -78°C → r.t., 22 h, 2. Oxone in sat. NaHCO₃, r.t., 2 h, 80% b) Ac₂O, DMAP, pyridine, r.t., 95% c) HF/Et₃N, THF, r.t., 85% d) TCDI, THF, reflux, 82% e) AIBN, TTMS, toluene, reflux, 82%

reduction was performed with AIBN as the radical initiator and tris(trimethylsilyl)silane (TTMSS) as the H-donor to yield **10a**, **10b** and **11a**, again in good yields (Scheme 1).

Synthesis of the phosphoramidite building blocks: The nucleosidation of building block **10b** (for nucleosidation of **10a** see supporting information) with the bases T, A^{Bz} and C^{Bz} was performed under Vorbrüggen conditions leading to close to 1:1 mixtures of anomers **12a/b**, **13a/b** and **14a/b** in 75-85% yields that were not separable by standard chromatography techniques (Scheme 2). Subsequent deacetylation under mild conditions yielded **15a/b**, **16a/b** and **17a/b**. We decided to invert the configuration at C(6') at this stage. Therefore the free nucleosides **15a/b**, **16a/b** and **17a/b** were converted into the corresponding C(6') mesylates **21a/b**, **22a**, **22b** and **23a/b**. At this point it was possible to separate the α - and β -anomers of **22** by column chromatography, while **21** and **23** had unfortunately still to be taken forward as mixtures of anomers. Subsequent acetylation of O(3') followed by displacement of the 6'-mesyl function by CsOAc in DMSO yielded **24a/b**, **25b** and **26a/b**. Saponification (→ **27a/b**, **28b**, **29a/b**) and subsequent tritylation gave compounds **30a**, **30b**, **31b**, **32a**, **32b**. As already observed in other cases the tritylated nucleosides **30** and **32** were now separable by chromatography and isolated as pure isomers. The relative configuration at the centers C(1') in **30b**, **31b** and **32b** was ascertained by ¹H-NMR-ROESY (supplementary information). The treatment of the beta-nucleosides **30b**, **31b** and **32b** with CEP-Cl under standard conditions finally yielded the desired phosphoramidites **33b**, **34b** and **35b**.

For the synthesis of the iso-bicyclo guanosine, a slightly different protecting group strategy had to be employed due to the notoriously high degree of insolubility imparted by the guanine base. Thus the O(3') and O(5') acetyl groups in **10b** were replaced by TBS groups, leading to **37b** that was subjected to nucleosidation with 2-amino-6-chloropurine under classical Vorbrüggen conditions giving nucleosides **38a/b** in an anomeric ratio of 1:1 in acceptable yields (Scheme 3). Treatment of **38a/b** with sodium hydride and 3-hydroxypropionitrile exchanged the C(6')-chloro substituent by oxygen (→ **39a/b**). Further protection of the exo amino function of

the guanine base yielded amidine **40a/b**. In order to invert the configuration at C(6'), selective desilylation at this position was

Scheme 2. a) Thymine (2eq.), BSA (5eq.), TMSOTf (3eq.), MeCN, 0°C – rt, 85% / Benzoyl-adenine (2eq.), BSA (4eq.), TMSOTf (0.3eq.), MeCN, 85°C, 75% / Benzoyl-cytosine (2eq.), BSA (5eq.), TMSOTf (3eq.), 0°C – rt, 75% b) 0.2 M NaOH in 5:4:1 THF/MeOH H₂O, 0°C, 75-90% c) MsCl (1 eq.), Pyridine, 0°C → r.t., 60-70% d) Ac₂O, DMAP, pyridine, r.t., 80-91% e) CsOAc, DMSO, 90°C, 81-93% f) 0.2 M NaOH in 5:4:1 THF/MeOH, H₂O, 0°C, 60-84% g) DMT-Cl, Pyridine, r.t., 48% (30a), 40% (30b), 90% (31b), 62% (32a), 30% (32b) h) Hünig's Base, CEP-Cl, MeCN, r.t., 72-87%

desirable. This goal was achieved by the use of HF/Et₃N (→**41a/b**). Despite desilylation with fluoride ions is known to be unspecific^[12] we observed high selectivity towards deprotection of the sterically less hindered O(6'). The free hydroxyl group in **41a/b** was then mesylated (→**42a/b**), inverted (→**43a/b**) and the acetyl function removed with concomitant removal of the amidine protecting group, leading to the chromatographically separable anomers **44a** and **44b**. Reprotection of the N(2) amino function in the β-anomer (→**45b**) and DMT protection using standard conditions yielded **46b** in good yields. Subsequent deprotection with TBAF (→**47b**) followed by phosphitylation finally concluded the synthesis of the iso-bicyclo-G building block **48b**. Again, the relative configuration at C(1') was confirmed by ¹H-NMR-ROESY on compound **47b** (supporting information).

Oligonucleotide synthesis: Modified oligonucleotides were synthesized using standard phosphoramidite chemistry on a DNA synthesizer on the 1.3 μmol scale. Either natural deoxynucleoside derived CPG solid support or, for the fully modified strands, a universal solid support was used. For the incorporation of the iso-bicyclo nucleoside building blocks the coupling time was increased to 9 min. All other steps remained unchanged. After chain assembly the oligonucleotides were cleaved from the solid support and deprotected by aminolysis at 70°C over night, then purified by reverse phase or ion exchange HPLC. The expected masses were confirmed by ESI mass spectrometry.

Biophysical properties of oligonucleotides containing iso-bicyclo thymidines: Oligonucleotides **S1-S4** containing single and consecutive iso-

bicyclo thymidine modifications were synthesized and their pairing properties with complementary DNA and RNA investigated by UV-melting curves at 260 nm. (Table 2, Figure S1 and S2, supporting information). Analysis of the *T_m* data revealed a stabilization of 1°C/mod with complementary DNA. This occurs in all four duplexes independently of the position or the number of modifications in the strand. In the case of RNA, the iso-bc-T modification seems to be stabilizing for single incorporations but destabilizing for consecutive incorporations. As expected, the CD-spectra of **S1-S4**

with complementary DNA and RNA do not deviate significantly in shape from that of **S5**, indicating minor structural perturbations imparted by the iso-bc-T residues (Figure S5 and S6, supporting information).

Table 2. *T_m* values derived from UV-melting-temperature experiments at 260nm. Conditions: 10 mM NaH₂PO₄, 150 mM NaCl, pH 7.0, c = 1.2 μM strand concentration.

	Sequence ^[a]	Complementary DNA	Complementary RNA
S1	5'-d(GGAtGTTCTCGA)-3'	48.0	49.0
S2	5'-d(GGATGtCTCGA)-3'	49.0	47.5
S3	5'-d(GGATGTTctCGA)-3'	48.0	50.0
S4	5'-d(GGAtGttCtCGA)-3'	51.0	49.5
S5	5'-d(GGATGTTCTCGA)-3'	47.0	49.0

[a] upper case letters: natural nucleotides; lower case letters: iso-bc-nucleotides

Scheme 3. a) 2-amino-6-chloropurine, BSA, TMSOTf, MeCN, 60°C, 5 h, 64% b) NaH, 3-hydroxypropionitrile, THF, 0°C-r.t. 3h c) N,N-dimethylacetamide, DMF, 55°C, 3 h, 71% over two steps d) HF/Et₃N, THF, r.t., 55% e) MsCl, pyridine, r.t., 92% f) CsOAc, DMSO, 85°C, 16 h, 85% g) 1 M KOH in 5/3 MeOH/H₂O, 60°C, 42% (53b), 20% (53a) h) N,N-dimethylacetamide, DMF, 55°C, 3 h, 64% i) DMT-Cl, pyridine, r.t., 16 h, 94% j) TBAF, THF, r.t., 5h, 70% k) Hünig's base, Cep-Cl, MeCN, r.t., 1h, 88%

Synthesis and properties of fully modified oligonucleotides containing iso-bc-T and iso-bc-A: As for the synthesis with single iso-bc-T incorporations, a non-self-complementary sequence motif was chosen. **S6** and **S7** (Table 3) are complementary and can therefore give insight into the self-pairing of iso-bicyclo DNA. The melting curves of **S6** and **S7** with complementary DNA and RNA partially confirm the results obtained with the thymidine modified oligonucleotides. All duplex melting curves reflect cooperative and reversible melting (Figure 3). The iso-bc modifications stabilize duplexes with DNA, but not as predicted from single incorporations with 1°C per modification. The overall stabilization is +2°C (**S6**) and +3°C (**S7**) per duplex, respectively (Table 3).

Table 3. T_m values derived from UV-melting-temperature experiments at 260nm. Conditions: 10 mM NaH_2PO_4 , 150 mM NaCl, pH 7.0, $c = 1.2 \mu\text{M}$ strand concentration. [a] not measured

Sequence	T_m vs DNA antiparallel	T_m vs RNA antiparallel	T_m vs DNA parallel
S6 6'-d(ataattaataa)-3'	25.1	<10	21.9
S7 6'-d(ttattaaattat)-3	25.9	<10	28.1
S8 5'-d(ATAATTTAATAA)-3'	23.2	n.m. ^[a]	19.8
S9 5'-d(TTATTAAATTAT)-3'	23.2	11.2	n.m. ^[a]

In the case of RNA as complement duplex destabilization with a T_m value below 10°C is observed. This was predicted from the earlier experiments where we have shown that single incorporations stabilize the duplex and consecutive modifications destabilize it. Thermal denaturation experiments were also performed for the fully modified duplex **S6:S7**. The T_m in this case is remarkably high with

Figure 3. UV -melting curves (260 nm) of the AT-duplexes. Conditions: 10 mM NaH_2PO_4 , 150 mM NaCl, pH 7.0, $c = 1.2 \mu\text{M}$ strand concentration. ■ **S6:RNA**, ▲ **S7:RNA**, ▼ **S6:S7**, ○ DNA:RNA, + DNA:DNA, * **S6:DNA**, ◆ **S7:DNA**

a value of 41.9 °C which is almost twice as high as that for the natural DNA duplex. Furthermore, to check the specificity for the antiparallel orientation in the duplex, melting temperatures for the parallel duplexes with DNA were measured (Figure S3, supporting information). Both, **S6** and **S7**, showed T_m values that are comparable to the ones measured for the antiparallel duplexes (-3°C for **S6** and +2°C for **S7**, Table 3). The same is true for the natural duplex, which was slightly destabilized by -3°C compared to the antiparallel duplex.

It thus appears that, much like natural DNA,^[13] also iso-bc-AT sequences have the potential to form parallel reverse Watson-Crick duplexes. It also becomes clear that iso-bc-AT-oligonucleotides do not have a considerable stabilizing effect on duplexes with DNA but have a significant destabilizing effect on duplexes with RNA as complement. In contrary, the fully unnatural duplex is significantly

more stable compared to pure DNA or hybrid (iso-bicyclo-DNA/DNA) duplexes. This is not uncommon for sugar-modified oligonucleotide analogues, such as HNA^[14] or tc-DNA, and reflects most likely a more perfect geometric match of the repeating backbone units in homo-backbone duplexes as compared to hetero-backbone duplexes.

In order to get insight into the structural properties of these AT duplexes, circular dichroism (CD) spectra were measured. The CD spectra for the natural duplex **S8:S9** as well as for the hybrid duplex **S6:S9** (Figures S7 and S8, supplementary information) showed a B-like conformation and, in the case of the fully modified duplex **S6:S7** the CD spectrum showed a signature that is significantly different from A-, B- or Z-DNA (Figure 4). The CD traces of the single strands (at high temperature) are similar to the unmodified ones and the hybrid duplexes. In the paired state, however, the CD shows an intense negative band between 290 and 260 nm, which mirrors the band of the unmodified duplex in this part of the spectrum (Figure 4). For the parallel duplexes in all three cases a B-type conformation is observed (Figure S9, supplementary information).

Figure 4. CD spectrum of the duplex **S6:S7** at different temperatures. Conditions: 10 mM NaH_2PO_4 , 150 mM NaCl, pH 7, $c = 1.2 \mu\text{M}$ strand concentration.

Reported CD spectra of natural, parallel AT-duplexes were found to be sequence specific: A parallel duplex with alternating AT base pairs shows a negative band at 290 nm^[15] whereas a $\text{d}(\text{A})_{10}\text{.d}(\text{T})_{10}$ hairpin shows a spectrum close to the one obtained in our case^[13]. However, the negative band between 260 and 290 nm in the **S6:S7** duplex is most likely not the result of a partial parallel iso-bc-AT duplex structure since achieving a melting temperature of 41.9°C with a minimum of 6 mismatches in a dodecamer seems very unlikely. Hence we hypothesize that there exists a different, yet undetermined duplex conformation for pure iso-bc-AT duplexes.

Thermodynamics of duplex formation: Using standard curve fitting procedures to experimental melting curves^[16] we calculated the thermodynamic data of duplex formation of the fully modified duplex **S6:S7** as well as the hybrid duplex **S6:S9** and compared the data to that of the natural duplex **S8:S9** (Table 4). From there it appears that the natural duplex **S8:S9** is enthalpically favored over the fully modified duplex. The free energy $\Delta G^{25^\circ\text{C}}$ is, as expected from the T_m -data, in favor of the fully modified duplex **S6:S7**. Thus the fully modified duplex is entropically favored which is in agreement with its reduced conformational flexibility. The hybrid duplex shows a somewhat unusually high enthalpy ΔH , which is

counterbalanced by the entropy term, indicating enthalpy/entropy compensation to be operative.

Table 4. Thermodynamic data of duplex formation from curve fitting to the experimental melting curve. Conditions: 10 mM 10 mM NaH₂PO₄, 150 mM NaCl, pH 7.0, c= 1.2 μM strand concentration

Duplex	ΔH (kcal·mol ⁻¹)	ΔS cal·mol ⁻¹ ·K ⁻¹)	ΔG ^{25°C} (kcal·mol ⁻¹)
S6:S7	-73.0	-202.8	-12.6
S6:S9	-84.7	-254.0	-8.9
S8:S9	-76.6	-228.9	-8.3

We also investigated the influence of salt concentration on duplex stability by varying the NaCl concentration of the buffer in a range from 0.05 M – 1.5 M. The uptake of sodium ions upon duplex formation helps to stabilize the duplex by reducing the repulsion between the phosphate groups. Since the negative charge density is higher in a duplex than in single strands, counter ions are screened upon duplex formation. As expected, an increase of the T_m values with increasing NaCl concentration was observed (Figure 5). The duplexes **S8:S9** and **S6:S9** both doubled their T_m values within the 30-fold increase of salt concentration. The fully modified duplex **S6:S7** increased its T_m by 35°C, which is slightly more than twice the starting value at 0.05 M NaCl. We further determined the relative counter ion uptake Δn (Table 5) according to classical polyelectrolyte theory,^[17] using the transition enthalpy (ΔH) data from Table 4.

$$\Delta n = -2\Delta H/RT_m^2 \cdot \delta T_m / \delta (\ln[\text{NaCl}])$$

Table 5. Calculated counter ion uptake. Conditions: 10 mM NaH₂PO₄, 200 mM NaCl, pH 7

	S8:S9	S6:S9	S6:S7
Δn	1.1	1.6	2.1
δT _m /δ(ln[NaCl])	5.3	7.2	11.8

The fully modified iso-bc system **S6:S7** screens about twice as much counter ions upon duplex formation than the corresponding unmodified duplex and about a third more than the hybrid duplex. This is in agreement with a higher degree of spatial compression of the phosphate groups upon transition from single strands to duplex. Whether this is due to a more compressed duplex structure or a more relaxed single strand structure remains unknown at this point.

Synthesis and properties of oligonucleotides containing all four iso-bc-nucleosides: Two fully modified sequences containing iso-bc-A, -T, -G, and -C residues were synthesized: A dodecamer (**S10**) for the investigation of the pairing properties with complementary DNA and RNA and a self-complementary hexamer (**S11**) to get further insight into the structure of fully modified duplexes (Table 6). Thermal melting of **S10** with complementary DNA shows, as all modified DNA sequences, a cooperative and reversible melting behavior (Figure 6). Again, a stabilization of the duplex was observed but, even including the more stable CG base pairs, the difference in melting temperature is small (+4°C / duplex) and comparable to the one observed in the AT-series (Table 6). In addition, the melting behavior of **S10** with a parallel DNA complement was investigated. No cooperative transition was observed revealing that iso-bc-DNA, as DNA, strongly prefers antiparallel Watson-Crick pairing in sequences containing all four base-pairs. For the hexamer **S11** a very stable duplex was found with for GC base-pairs usually low hyperchromicities at 260 nm

(Figure 6). This again confirms that fully modified iso-bc-duplexes are very stable, irrespective of the base composition.

Figure 5. Plot of the T_m vs $\ln[\text{NaCl}]$; 10 mM NaH₂PO₄, 50 mM-1.5 M NaCl, PH = 7.0, c= 1.2 μM strand concentration. ▼ DNA:DNA, ■ S6:S7, ● S6:DNA

Figure 6. UV melting curves (260 nm) for the modified sequence S7 with DNA (left) and RNA (right). Conditions: 10 mM NaH₂PO₄, 150 mM NaCl, pH 7.0, c= 1.2 μM strand concentration. ■ S11, ○ RNA hexamer, ▲ S10:DNA, ▼ DNA:DNA, * S10:RNA, + DNA:RNA

Table 6. T_m data for fully modified iso-bc-oligonucleotides containing all four bases. Conditions: 10 mM NaH₂PO₄, 150 mM NaCl, pH 7.0, strand concentration for all dodecamers: c=1.2 μM. Total strand concentration for the natural hexamers: 2.4 μM and for S11: 4.8 μM

	Sequence	DNA antiparallel	RNA antiparallel	iso-bc duplex
S10	6'-d(cctactagagct)-3'	51.0 (+4)	30.0 (-11.5)	--
S11	6'-d(cctagg)-3' ^[b]	<10	34.5	40.7

[a] n.d.: not detected [b] self-complementary duplex: T_m data refer to the resp. backbone type.

CD spectra of the hybrid duplex (**S10:DNA**, Figure 7) revealed a completely different curve shape compared to the unmodified duplex (Figure S13, supplementary information), indicating substantial deviation from classical A or B-type structures. In contrast, in the case of the RNA complement, a typical A-form is observed with comparable spectra for the unmodified and the modified duplex. The CD signature of the **S11:S11** duplex, however, shows an intense negative cotton effect at 290 nm and a positive cotton effect at 260 nm (Figure 7). It thus deviates significantly from that of the self-complementary RNA hexamer (A-

type conformation, data not shown) and also to some extent from the fully modified iso-bc-AT duplex **S6:S7** (Figure 3). It thus shows

Figure 7. CD spectra of **S11:S11**, **S10:DNA** and **S10:RNA**. Conditions: 10 mM NaH_2PO_4 , 150 mM NaCl, pH 7, $c = 1.2 \mu\text{M}$ strand concentration.

some similarities to that of Z-DNA^[18] which, given the high GC content, could be a possible structure for **S11**. However, more high resolution structural work is needed to get a reliable picture of the 3D structure.

Mismatch discrimination: To test the base-pairing selectivity of the iso-bc-DNA system, the melting temperatures of different mismatched duplexes complementary to **S10** were measured. A thymidine residue in the complementary DNA sequence was replaced by an A, C or G and the corresponding T_m values were determined (Table 7).

Table 7. Mismatch discrimination. In parentheses are the ΔT_m values relative to the matched duplex. Conditions: 10 mM NaH_2PO_4 , 150 mM NaCl, pH 7.0, $c = 1.2 \mu\text{M}$ strand concentration.

duplex	X = A	X = G	X = C	X = T (match)
6'-d(cctactagact)-3' (S10)	37 (-14)	43 (-8)	33 (-18)	51
5'-d(ACGXCTTGTAGG)-3'				
5'-d(CCTACAAGAGCT)-3'	34 (-13)	39 (-8)	30 (-17)	47
5'-d(ACGXCTTGTAGG)-3'				

In all cases thermal destabilizations in the mismatched duplexes were observed. The A-C mismatch was the strongest discriminating followed by the A-A and the A-G mismatches. The decrease is generally of about the same extent as in DNA, indicating an equal selectivity of the two Watson-Crick pairing systems.

Serum stability: The serum stability of **S10** was measured in heat deactivated fetal bovine serum (FBS) in which the predominant nucleases are the 3'-exophosphodiesterases.^[19] As a control the stability of the corresponding natural DNA complement was tested, too. After incubation at 37°C in medium containing 10% FBS, aliquots were taken in regular intervals and after ethanol precipitation analysed by PAGE. The gel was visualized with *stains-all* solution (Figure 8).

The resulting gel shows that **S10** is stable over a period of at least 21h without signs of degradation. In contrast, the DNA complement is substantially hydrolyzed after this period of time, indicating a significantly higher degree of biostability of iso-bc-DNA.

Figure 8. PAGE analysis of the serum stability of DNA (left) and iso-bicyclo DNA (right). 1: 0 h, 2: 0.5 h, 3: 2 h, 4: 6.5 h, 5: 21 h

RNase H activity: Due to its ability to cleave DNA/RNA heteroduplexes, it is desirable for chemically modified oligonucleotides designed to ablate an RNA of interest, to be able to activate the endogenous enzyme RNase H. This is, however, difficult to achieve since only a small number of DNA analogues is known to be compatible with RNase H activity.^[20] To investigate this, the RNA complement of **S10** was 5'-labeled with $[\gamma\text{-}^{32}\text{P}]\text{-ATP}$ and T4 polynucleotide kinase (T4 PNK) and annealed to **S10**. The natural RNA/RNA and the hybrid DNA/RNA duplexes served as negative and positive control. As expected, the RNA/RNA duplex did not show any RNase H mediated degradation, while the DNA/RNA hybrid turned out to be a good substrate. The **S10**/RNA duplex showed no signs of RNA cleavage after treatment with RNaseH, clearly showing that iso-bc-DNA does not elicit RNaseH activity (Figure 9).

Figure 9 PAGE analysis of the RNase H activity of the duplexes: RNA:32P-RNA (C12:32P-C9), iso-bicyclo-DNA:32P-RNA (S7:32P-C9), DNA:32P-RNA (C8:32P-C9). 1: 5 min., 2: 45 min., 3: 120 min., 4: 300 min.

Discussion

We synthesized all four iso-bicyclo nucleosides and incorporated them successfully into DNA. Single iso-bicyclo T incorporations in natural DNA showed stable duplexes with complementary DNA and RNA. Consecutive incorporations destabilize the RNA hybrid. The same result was obtained for the fully modified AT duplexes where a stabilized duplex with DNA and a significantly destabilized duplex with complementary RNA was found. An interesting finding in the AT series was the very stable self-duplex with a T_m of 41.9°C. The CD spectrum of this fully modified iso-bicyclo duplex (Figure 3) revealed a structure different from A- or B-form duplex.

It is known that the duplex conformation as revealed by CD-spectroscopy is dependent on the base sequence and on the salt concentration of the buffer. Increasing the salt concentration typically leads to a decrease of the long wavelength band between 290 and 260 nm corresponding to variants of B-DNA structures differing in the number of base pairs per helix turn.^[21] Vorlíčková

and Kypr investigated the conformational changes of poly(A-T) sequences at different CsF concentrations and found that the long wavelength part of the CD spectra falls off, inverts and becomes negative at high salt concentrations.^[22] They called that structure X-DNA and suggested that this X-DNA is a right handed anti-parallel double helix with Hoogsteen base-pairs that were found by Abrescia et al. some years ago.^[21, 23] In this Hoogsteen DNA^[23] the overall helical parameters are similar to that of B-DNA with the adenines in syn-conformation. Therefore one hypothesis is that the fully modified iso-bicyclo-AT duplex **S6:S7** forms such an X-DNA structure.

Further evidence for such a X-DNA structure comes from CD-experiments with **S6:S7** as well as the hybrid DNA duplexes of **S6** at different salt concentrations. While no major changes occur in the case of the unmodified duplex **S8:S9** and the hybrid duplex **S6:S9** (Figures S7 and S8, supplementary information), the CD of the fully modified duplex **S6:S7** shows a high dependence on the sodium chloride concentration (Figure S10, supplementary information). The negative band at 275 nm increases in intensity upon increasing the NaCl concentration. This could indeed be an indication of a partial structural transition from the more compact X- towards a B-type conformation when changing from high to low electrolyte concentration, which supports the preference of an X-type conformation of iso-bc-DNA duplexes at physiological salt concentration.

The fully modified iso-bc-AT oligonucleotides form also stable parallel duplexes. Parallel duplex formation in poly(dAT) sequences is well known and investigated.^[15, 24] They require reversed Watson-Crick base-pairs and their thermal stability is highly sequence dependent. This explains the variability in the T_m s for the two duplexes **S6** and **S7** with parallel complements. However, no melting transition was found for the fully modified **S10**, containing all four bases, with a parallel DNA complement, revealing that iso-bc-DNA prefers strictly antiparallel pairing in sequences containing also G-C base-pairs. These preferences are identical to that of natural DNA where parallel reversed Watson Crick is also restricted to AT sequences.

Iso-bc-DNA was found to be unable to activate RNase H in iso-bc-DNA/RNA hybrids. RNase H is known to preferably bind to A-form rather than B-form duplexes. Hence, as a consequence the enzyme binds RNA/RNA duplexes and DNA/RNA hybrids much tighter than a DNA/DNA duplex.^[25] The RNA in dsRNA duplexes is not cleaved since the 2'-OH groups affect the hydration pattern in the minor groove.^[26] Since the CD spectrum of the iso-bicyclo DNA/RNA duplex shows an A-like structure and is very similar to that of the DNA/RNA duplex, an activation of RNase H could have been expected. However, it has also been shown that the enzyme is very sensitive to structural changes within the minor groove. This is the reason why all 2' modified oligonucleotides (e.g. 2'-OME^[27]) as well as the sterically constrained (e.g. LNA^[28]; tcdNA^[9a]) do not activate RNase H.^[26] From this point of view it is not surprising that iso-bc-DNA is unable to do so.

Conclusions

We have achieved the synthesis of all four iso-bc-DNA building blocks starting from the silyl enolethers **1a** or **1b**. These phosphoramidites were successfully incorporated into natural deoxyoligonucleotides or were used for the synthesis of fully

modified iso-bc-DNA by standard solid phase DNA synthesis. Oligodeoxynucleotides containing single incorporations as well as fully modified iso-bc-DNA show stable duplexes with DNA complements with a slightly enhanced stability (ca. 0.3 °C/mod). RNA is discriminated as complement in all the investigated duplexes by ca 1°C/mod. All hybrid duplexes show B-conformation with DNA and A-conformation with RNA as judged from CD-experiments. Base mismatches are discriminated in the same way as in natural DNA. Fully modified iso-bicyclo oligonucleotides form very stable duplexes within their own backbone series that are of higher thermodynamic stability than the corresponding natural duplexes. Fully modified duplexes containing only AT base-pairs show a CD-signature that is significantly different from that of the canonical DNA conformations. Based on the available biophysical data we propose a double helical structure with Hoogsteen base-pairs. Furthermore, iso-bc-DNA is stable in bovine serum and does not activate RNase H.

Thus it appears that the phosphate shift from C(5') to C(6') in the bicyclic system is well tolerated in duplexes with DNA and less well in duplexes with RNA. Pure iso-bc-DNA duplexes, however, display considerable structural differences of a yet unknown type. The feature of iso-bc-DNA to stabilize DNA duplexes and discriminate RNA is interesting and could find possible applications in diagnostics, as e.g. in primers for PCR.

Experimental Section

General: All reactions were performed under Ar and in dried glassware. Anhydrous solvents for reactions were obtained by filtration through activated alumina or by storage over molecular sieves (4 Å). Column chromatography (CC) was performed on silica gel with an average particle size of 40 µm. All solvents for column chromatography were of technical grade and distilled prior to use. Thin-layer chromatography was performed on silica gel plates. Visualization was achieved either under UV light or by dipping in staining solution [CerIV-sulfate (10.5 g), phosphormolybdic acid (21 g), conc. H₂SO₄ (60 ml), H₂O (900 ml) or p-anisaldehyde (10 ml), conc. H₂SO₄ (10 ml), glacial acetic acid (2 ml), ethanol (180 ml)] followed by heating with a heat gun. NMR spectra were recorded at 300 or 400 MHz field width (¹H) in either CDCl₃ or CD₃OD. δ in ppm relative to residual undeuterated solvent CHCl₃: 7.26 ppm (¹H) and 77.16 ppm (¹³C); CHD₃OD: 3.31 ppm (¹H) and 49.0 ppm (¹³C), J in Hz. Signal assignments are based on DEPT and on ¹H-¹H and ¹H-¹³C correlation experiments (COSY/HMSC). High-resolution mass spectra were recorded on an Applied Biosystems Sciex QSTAR Pulsar.

(3*R*, 5*S*, 8*R*, 7*S*)-8-((*tert*-butyldimethylsilyl)oxy)-3-methoxyhexahydro-2*H*-cyclopenta[b]furan-3*a*,6-diyl diacetate **4b** A solution of **2b** (4.3g, 14.2 mmol) in pyridine (35 ml) was cooled to 0°C and DMAP (171 mg, 1.4 mmol) and Ac₂O (4.0 ml, 42.7 mmol) were added. The mixture was stirred for 16 h at r.t. and, after cooling to 0°C, carefully quenched and washed with sat. NaHCO₃. The aqueous layers were extracted with DCM. The combined organic layers were dried over MgSO₄ and evaporated. FC (ethyl acetate/hexane 1:3) yielded **4b** (4.9 g, 12.6 mmol, 90%) as a white solid. *R*_f: 0.9 (hexane/ethyl acetate 1:1), HR-MS (ESI⁺, MeCN) for C₁₈H₃₂O₇Si. calc: 411.1813, found: 411.1810 (M + Na⁺), ¹H NMR (400 MHz, CDCl₃) δ 5.24 (*m*, 1H), 5.06 (*d*, 1H, *J* = 5.3), 4.36 (*d*, 1H, *J* = 6.4), 4.20 (*dd*, 1H, *J* = 8.6, 6.4), 3.36 (*s*, 3H), 2.86 (*dd*, 1H, *J* = 13.9, 7.6), 2.55 (*d*, 1H, *J* = 13.8), 2.36 (*ddd*, 1H, *J* = 13.8, 5.7, 1.8), 2.02 (*s*, 6H), 1.76 (*ddd*, 1H, *J* = 13.8, 9.7, 1.6), 0.90 (*s*, 9H), 0.11 (*s*, 3H), 0.08 (*s*, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 170.55, 170.17, 105.42, 89.29, 85.33, 77.97, 75.80, 54.62, 47.69, 40.15, 25.89, 21.62, 21.16, -4.60, -4.71.

(3*R*, 5*S*, 8*R*, 7*S*)-8-hydroxy-3-methoxyhexahydro-2*H*-cyclopenta[b]furan-3*a*,6-diyl diacetate **6b** A solution of **4b** (10.4 g, 26.8 mmol) in THF (80 ml) was cooled to 0°C. HF/Et₃N (37% HF, 23 ml, 53.6 mmol) was added and the solution was allowed to warm to r.t. The reaction mixture was stirred for 60 h at r.t. and subsequently quenched with silica. The solvent was evaporated and the crude mixture purified by FC (ethyl acetate/hexane 1:1). **6b** (5.9 g, 21.5 mmol, 80%) was obtained as a colourless oil. *R*_f: 0.4 (ethyl acetate/hexane 1:1), HR-MS (ESI⁺, MeCN/H₂O, 1% HF) for C₁₂H₁₈O₇. calc: 279.09447, found: 297.09538 (M + Na⁺), ¹H-NMR (300 MHz, CDCl₃): 5.10-5.13 (*m*, 2H), 4.53 (*d*, *J* = 6.4, 1H), 4.10 (*m*, 1H), 3.39 (*s*, 3H); 2.78-2.80 (*m*, 2H), 2.48 (*m*, 2H), 2.03 (*s*, 3H); 2.00 (*s*, 3H), 1.95-1.86 (*m*, 1H), ¹³C NMR (75 MHz, CDCl₃) δ 171.06, 170.09, 106.93, 89.23, 85.93, 78.71, 74.79, 55.79, 47.14, 39.93, 21.51, 21.14.

(3*R*, 5*S*, 8*R*, 7*S*)-8-((1*H*-imidazole-1-carbonthioyl)oxy)-3-methoxyhexahydro-2*H*-cyclopenta[*b*]furan-3*a*,6-diyl diacetate **8b** To a solution of **6b** (3.2 g, 11.7 mmol) in THF (60 ml) was added TCDI (4.2 g, 23.3 mmol). The yellow solution was refluxed at 75°C for 3h. The THF was then evaporated and the crude mixture was purified by FC (ethyl acetate/hexane 1:1) to yield **8b** (4.2g, 10.9 mmol, 93%) as a yellow foam. *R*_f 0.40 (ethyl acetate/hexane 1:1), HR-MS (NSI⁺, EtOAc) for C₁₆H₂₀N₂O₇S. calc: 385.1064, found: 385.1051 (M + H⁺), ¹H NMR (400 MHz, CDCl₃) δ 8.39 (m, 1H), 7.67 (m, 1H), 7.04 (m, 1H), 5.92-5.85 (m, 1H), 5.70-5.67 (m, 1H), 5.08, 5.06 (2m, 2H), 3.34 (s, 3H), 2.94 (dd, 1H, *J* = 13.9, 8.1), 2.58 (d, 1H, *J* = 14.0), 2.49 (ddd, 1H, *J* = 14.1, 5.7, 1.8), 2.14-2.10 (m, 1H), 2.08, 2.05 (2s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 183.54, 170.40, 170.29, 137.40, 131.24, 118.26, 106.14, 89.25, 84.34, 82.33, 73.85, 55.33, 47.82, 39.38, 21.55, 21.15

(3*R*, 5*S*, 7*S*)-3-methoxyhexahydro-2*H*-cyclopenta[*b*]furan-3*a*,6-diyl diacetate **10b** The sugar **8b** (4.2 g, 10.9 mmol), AIBN (270 mg) and TTMS (6.7 ml, 22 mmol) were dissolved in toluene (87 ml) and stirred for 2 h at 85°C. The toluene was then evaporated and the crude mixture purified by FC (ethyl acetate/hexane 1:3). Compound **10b** (2.6 g, 10.1 mmol, 92%) was obtained as a colourless oil. *R*_f 0.6 (ethyl acetate/hexane 1:1), HR-MS (NSI⁺, MeOH) for C₁₂H₁₆O₆. calc: 281.0996, found: 281.1002 (M + Na⁺), ¹H NMR (300 MHz, CDCl₃) δ 5.39-5.31 (p, 1H, *J* = 6.3), 5.04 (dd, 1H, *J* = 5.6, 0.7), 4.71 (dd, 1H, *J* = 7.0, 3.5), 3.33 (s, 3H), 2.78-2.71 (dd, 1H, *J* = 14.6, 6.2), 2.60 (d, 1H, *J* = 14.0), 2.33 (ddd, 1H, *J* = 14.2, 5.7, 0.8), 2.29-2.07 (m, 3H), 2.02, 2.00 (2s, 6H). ¹³C NMR (75 MHz, CDCl₃) δ 170.58, 170.37, 106.61, 92.63, 87.86, 75.03, 54.99, 46.55, 44.15, 39.02, 21.65, 21.28.

(3'*S*, 6'*S* (6'*R*))-1-(3', 6'-Di-*O*-acetyl-2'-deoxy-3',5'-ethano- α - and - β -D-ribofuranosyl] thymine **12a/b** Thymine (293 mg, 2.3 mmol) was suspended in MeCN (12 ml) and BSA (1.4 ml, 5.8 mmol) was added. The suspension was stirred until the solution became clear. The solution was then cooled to 0°C and **10b** (300 mg, 1.2 mmol, dissolved in 6 ml MeCN) and TMSOTf (0.63 ml, 3.5 mmol) were added. After 1 h at 0°C the mixture was allowed to warm to r.t. and the stirring was continued for another 16 h. It was then diluted with ethyl acetate and washed with sat. NaHCO₃. Purification by FC (ethyl acetate/hexane 4:1) yielded the desired nucleoside **12a/b** (355 mg, 1.0 mmol, 87%) in an anomeric ratio of approx. α/β 1:1 as a white foam. *R*_f 0.49 (ethyl acetate/hexane 4:1), HR-MS (NSI⁺, MeCN) for C₁₆H₂₀N₂O₇. Calc. 375.1163, found 375.1145 (M + Na⁺), ¹H NMR (400 MHz, CDCl₃) δ 8.29 (m, 2H), 7.27 (s, 1H), 7.11 (s, 1H), 6.12 (m, 2H), 5.23 (m, 2H), 4.93 (dd, 1H, *J* = 6.4, 3.1), 4.56 (d, 1H, *J* = 5.6), 2.86 (m, 2H), 2.79 (ddd, 1H, *J* = 13.8, 6.3, 1.3), 2.66 (m, 1H), 2.54 (m, 1H), 2.36 (m, 1H), 2.25 (m, 2H), 2.16 (m, 1H), 2.10 (m, 2H), 2.08 (s, 3H), 2.06 (s, 3H), 2.04 (2s, 6H), 2.00 (m, 1H), 1.96 (m, 3H), 1.95 (m, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 170.69, 170.49, 170.35, 170.15, 163.73, 163.44, 150.30, 150.28, 135.31, 134.44, 112.04, 111.11, 91.21, 90.17, 87.69, 86.78, 85.33, 83.74, 73.65, 73.23, 44.46, 44.35, 43.64, 43.37, 37.84, 36.47, 21.73, 21.63, 21.19, 21.16, 12.86, -1.73.

(3'*S*, 6'*S*)-N6-Benzoyl-9-(3', 6'-Di-*O*-acetyl-2'-deoxy-3',5'-ethano- α - and - β -D-ribofuranosyl] adenine **13a/b** To a suspension of N6-benzoyl-adenine (926 mg, 3.9 mmol) in MeCN (15 ml) was added BSA (1.9 ml, 7.6 mmol). The mixture was stirred at r.t. until the solution was clear. **10b** (500 mg, 1.9 mmol, solved in 4 ml MeCN) and TMSOTf (0.1 ml, 0.6 mmol) were added and the solution was stirred for 2 h at 85°C. After cooling to r.t. the mixture was quenched with sat. NaHCO₃ and extracted with ethyl acetate. The combined organic layers were dried over MgSO₄ and evaporated. FC (3% methanol in DCM) yielded **13a/b** (654 mg, 1.4 mmol, 74%) in an anomeric ratio of ~1:1 as a white foam. *R*_f 0.65 (10% methanol in DCM), HR-MS (NSI⁺, MeOH) for C₂₃H₂₃N₅O₆. calc: 466.1721, found: 466.1724 (M + H⁺), ¹H NMR (300 MHz, CDCl₃) δ 8.81, 8.79 (2s, 2H), 8.24, 8.15 (2s, 2H), 8.03 (m, 4H), 7.64-7.59 (m, 2H), 7.55-7.50 (m, 4H), 6.45 (dd, 1H, *J* = 6.9, 2.7), 6.34 (dd, 1H, *J* = 8.4, 6.4), 5.55-5.46 (m, 1H, H-C(6')), 5.31-5.21 (m, 1H), 4.89 (dd, 1H, *J* = 6.1, 1.0), 4.73 (dd, 1H, *J* = 6.5, 1.7), 3.44 (dd, 1H, *J* = 15.4, 2.7), 3.03-2.90 (m, 4H), 2.88-2.81 (m, 1H), 2.45-2.36 (m, 2H), 2.22-2.12 (m, 4H), 2.12 (s, 3H), 2.06, 2.05 (2s, 6H), 1.95 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 170.60, 170.55, 170.47, 170.21, 164.72, 153.09, 152.97, 149.89, 149.72, 141.43, 141.25, 133.85, 133.07, 133.03, 129.13, 128.07, 123.67, 91.03, 90.99, 87.65, 86.25, 85.85, 84.84, 77.55, 77.23, 76.91, 73.46, 73.26, 44.25, 44.17, 43.77, 37.02, 36.88, 21.81, 21.52, 21.23, 21.18.

(3'*S*, 6'*S*)-N6-Benzoyl-1-(3', 6'-Di-*O*-acetyl-2'-deoxy-3',5'-ethano- α - and - β -D-ribofuranosyl] cytosine **14a/b** N-Benzoylcytosine (833 mg, 3.9 mmol) was suspended in MeCN (20 ml), BSA (2.3 ml, 9.5 mmol) was added and the suspension was stirred until the solution became clear. The solution was then cooled to 0°C and **10b** (500 mg, 1.9 mmol, dissolved in 20 ml MeCN) and TMSOTf (1 ml, 3.9 mmol) were added. After 1 h at 0°C the mixture was allowed to warm to r.t. and the stirring was continued for another 16 h. It was diluted with ethyl acetate and washed with sat. NaHCO₃. Purification by FC (ethyl acetate/hexane 4:1) yielded the desired nucleoside **14a/b** (638 mg, 1.5 mmol, 76%) in an anomeric ratio of α/β 1.5:1 as a white foam. *R*_f 0.26 (ethyl acetate/hexane 4:1), HR-MS (NSI⁺, MeCN) for C₂₂H₂₃N₅O₇. calc: 442.1609, found: 442.1617 (M + H⁺), ¹H NMR (300 MHz, CDCl₃) δ 8.87 (br, 2H), 7.92 (m, 4H), 7.63-7.47 (m, 8H), 6.10 (m, 2H), 5.20 (m, 2H), 5.03 (dd, 1H, *J* = 6.8, 3.2), 4.66 (d, 1H, *J* = 5.7), 3.19 (dd, 1H, *J* = 14.8, 5.4), 2.91 (dd, 1H, *J* = 15.4, 6.5), 2.70 (m, 3H), 2.30 (m, 3H), 2.25-2.11 (m, 5H), 2.07 (s, 3H), 2.04, 2.03 (2s, 6H), 1.99 (m, 1H), 1.93 (s, 3H). ¹³C NMR (101 MHz, MeOD) δ 172.40, 172.25, 172.03, 171.74, 164.98, 146.02, 145.77,

134.66, 134.14, 134.12, 130.47, 129.84, 129.57, 129.17, 129.14, 123.36, 120.19, 98.89, 98.11, 92.31, 92.07, 91.40, 90.17, 89.95, 89.44, 88.06, 87.65, 75.13, 61.55, 45.90, 45.44, 44.12, 43.44, 38.32, 37.57, 21.47, 21.30, 20.90, 20.88, 20.86, 14.45.

(3'*S*, 6'*S*)-1-(2'-Deoxy-3',5'-ethano- α - and - β -D-ribofuranosyl] thymine **15a/b** The nucleoside **12a/b** (480 mg, 1.36 mmol) was dissolved in 0.2 M NaOH in 5:4:1 THF/methanol/H₂O (65 ml) at 0°C. The solution was stirred for one hour at 0°C and quenched by the addition of ammonium chloride. The solvents were then evaporated and the remains absorbed on silica gel. Purification by FC (10% methanol in DCM) yielded compound **15a/b** (294 mg, 1.1 mmol, 81%) in an anomeric ratio of α/β ~1.25:1 as a white foam. *R*_f 0.19 (10% methanol in DCM), HR-MS (NSI⁺, MeCN) for C₁₂H₁₆N₂O₅. Calc. 269.1132, found 268.1141 (M + H⁺), ¹H NMR (400 MHz, MeOD) δ 7.74 (s, 1H), 7.40 (s, 1H), 6.10 (m, 2H), 4.55 (dd, 1H, *J* = 6.6, 1.9), 4.38 (m, 1H), 4.28 (m, 1H), 4.18 (dd, 1H, *J* = 6.7, 1.0), 2.52 (dd, 1H, *J* = 14.7, 7.1), 2.34 (m, 4H), 2.14 (m, 1H), 2.05 (m, 2H), H-C(7''), 1.90 (m, 3H), 1.89 (m, 3H), 1.88 (m, 2H), 1.80 (m, 1H), 1.71 (m, 1H). ¹³C NMR (101 MHz, MeOD) δ 166.55, 166.22, 152.52, 152.23, 138.60 (C-6), 137.07 (C-6), 111.98, 111.06, 91.65, 89.49, 88.58, 86.24, 85.50, 84.89, 71.98, 71.69, 49.33, 47.57, 46.94, 42.08, 41.15, 20.84, 12.51, 12.41.

(3'*S*, 6'*S*)-N6-Benzoyl-9-(2'-deoxy-3',5'-ethano- α - and - β -D-ribofuranosyl] adenine **16a/b** The nucleosides **13a/b** (606 mg, 1.3 mmol) were dissolved in 0.2 M NaOH in 5:4:1 THF/methanol/H₂O (90 ml) at 0°C. The solution was stirred for one hour at 0°C and quenched by the addition of ammonium chloride. The solvents were then evaporated and the remains absorbed on silica gel. Purification by FC (10% methanol in DCM) yielded compound **16a/b** (437 mg, 1.14 mmol, 88%) in an anomeric ratio of α/β ~1:1 as a white foam. *R*_f 0.2 (10% methanol in DCM), HR-MS (NSI⁺, MeOH) for C₁₉H₁₉N₅O₄. calc: 382.1510, found: 382.1512 (M + H⁺), ¹H NMR (300 MHz, MeOD) δ 8.76 (s, 1H), 8.70 (2s, 2H), 8.54 (s, 1H), 8.07 (m, 4H), 7.67-7.61 (m, 3H), 7.57-7.52 (m, 4H), 6.51 (dd, 1H, *J* = 7.2, 1.8), 6.33 (dd, 1H, *J* = 9.7, 5.3), 4.64-4.58 (m, 1H), 4.49 (d, *J* = 5.9), 4.37-4.26 (m, 2H), 2.91-2.83 (m, 2H), 2.72 (dd, 1H, *J* = 14.9, 7.3), 2.59 (dd, 1H, *J* = 13.5, 5.3), 2.48-2.37 (m, 2H), 2.21-2.07 (m, 2H), 1.92-1.74 (m, 4H). ¹³C NMR (75 MHz, MeOD) δ 153.36, 153.18, 152.95, 151.12, 151.08, 144.82, 144.29, 134.95, 133.88, 129.74, 129.41, 91.51, 90.22, 86.86, 86.06, 85.82, 85.41, 71.74, 71.54, 47.85, 47.03, 41.50, 41.32.

(3'*S*, 6'*S*)-N6-Benzoyl-1-(2'-deoxy-3',5'-ethano- α - and - β -D-ribofuranosyl] cytosine **17a/b** The nucleoside **14a/b** (316 mg, 0.72 mmol) was dissolved in 0.2 M NaOH in 5:4:1 THF/methanol/H₂O (50 ml) at 0°C. The solution was stirred for one hour at 0°C and quenched by the addition of ammonium chloride. The solvents were then evaporated and the remains absorbed on silica gel. Purification by FC (10% methanol in DCM) yielded compound **17a/b** (191 mg, 0.53 mmol, 74%) in an anomeric ratio of α/β ~1:1 as a white foam. *R*_f 0.36 (10% methanol in DCM), HR-MS (NSI⁺, MeCN) for C₁₈H₁₉N₅O₇. calc: 358.1397, found: 358.1387 (M + H⁺), ¹H NMR (300 MHz, MeOD) δ 8.26 (d, 1H, *J* = 7.5), 8.18 (d, 1H, *J* = 7.5), 7.99 (m, 2H), 7.96 (m, 2H), 7.63 (m, 4H), 7.55 (m, 4H), 6.10 (m, 2H), 4.72 (dd, 1H, *J* = 7.2, 2.1), 4.40-4.28 (m, 3H), 2.69 (dd, 1H, *J* = 13.7, 5.2), 2.59 (dd, 1H, *J* = 14.8, 6.7), 2.45 (dd, 1H, *J* = 14.8, 2.3), 2.38-2.29 (m, 2H), 2.23 (m, 1H), 2.14 (m, 1H), 1.96-1.85 (m, 3H), 1.81-1.69 (m, 2H). ¹³C NMR (101 MHz, MeOD) δ 164.81, 146.56, 146.10, 145.61, 134.74, 134.69, 134.10, 134.04, 129.83, 129.82, 129.16, 129.11, 98.80, 97.96, 92.69, 91.59, 90.35, 88.28, 87.99, 87.32, 85.96, 85.89, 82.54, 80.66, 79.66, 72.15, 71.89, 71.53, 58.32, 57.06, 57.01, 48.88, 48.31, 46.79, 45.89, 43.79, 42.06, 41.63, 41.24, 18.36.

(3'*S*, 6'*S*)-1-(2'-Deoxy-6'-*O*-(methylsulfonyl)-3',5'-ethano- α - and - β -D-ribofuranosyl] thymine **18a/b** A solution of **15a/b** (294 mg, 1.09 mmol) was dissolved in pyridine (15 ml) and cooled to 0°C. MsCl (85 μ l, 1.09 mmol) was added and the mixture was stirred at 0°C and over night at 4°C. After quenching by the addition of sat. NaHCO₃ and washing with ethyl acetate the combined organic layers were dried over MgSO₄ and purified by FC (3% methanol in DCM) to yield **18a/b** (250 mg, 0.72 mmol, 66%) in an anomeric ratio of α/β ~1.25:1 as a white solid. *R*_f 0.45 (10% methanol in DCM), HR-MS (NSI⁺, MeOH) for C₁₃H₁₈N₂O₇S. Calc. 347.0907, found 347.0902 (M + H⁺), ¹H NMR (400 MHz, DMSO) δ 11.35 (s, 1H), 11.27 (s, 1H), 7.68(s, 1H), 7.55(s, 1H), 6.08 (m, 2H), 5.18 (m, 1H), 5.07 (m, 1H), 4.50 (dd, 1H, *J* = 6.2, 2.0), 4.10 (dd, 1H, *J* = 7.1, 2.2), 3.22 (s, 3H), 3.20 (s, 3H), 2.52 (m, 3H), 2.20 (m, 5H), 2.08 (m, 2H), 1.99 (m, 1H), 1.90 (m, 1H), 1.81 (m, 3H), 1.79 (m, 3H). ¹³C NMR (101 MHz, DMSO) δ 163.80, 163.61, 150.45, 150.43, 136.44, 135.96, 109.70, 109.11, 88.09 (C4'), 86.61 (C4'), 85.51 (C1'), 84.10 (C1'), 83.45, 83.11, 80.49, 80.23, 45.40, 45.21, 45.05, 44.06, 38.32, 37.70, 37.55, 37.42, 12.2, 12.11.

(3'*S*, 6'*S*)-N6-Benzoyl-9-(2'-deoxy-, 6'-*O*-(methylsulfonyl)-3',5'-ethano- α - and - β -D-ribofuranosyl] adenine (**19a**, **19b**) A solution of **16a/b** (153 mg, 0.4 mmol) was dissolved in pyridine (6 ml) and cooled to 0°C. MsCl (0.03 ml, 0.4 mmol) was added and the mixture was stirred for 2 h at rt. Silica was then added and the pyridine was evaporated and shortly high vac dried. FC (7% methanol in DCM) yielded the corresponding anomers **19a** (105 mg, 0.23 mmol, 57%) and **19b** (73 mg, 0.16 mmol, 39%) as white foams. Analytical data for **19a**: *R*_f 0.5 (10% methanol in DCM), HR-MS (NSI⁺, MeOH) for C₂₀H₂₁N₅O₆S. calc: 460.1285, found: 460.1272 (M + H⁺), ¹H NMR (400 MHz, MeOD) δ 8.74 (2s, 2H), 8.09 (m, 2H), 7.65 (m, 1H), 7.57 (m, 2H), 6.56 (dd, 1H, *J* = 7.1, 2.6), 5.21-5.14 (m, 1H), 4.59 (dd, 1H, *J* = 6.3, 1.5), 3.12 (s, 3H), 2.92 (dd,

1H, $J = 14.9, 2.6$), 2.84 (*dd*, 1H, $J = 14.8, 7.2$), 2.67 (*ddd*, 1H, $J = 13.4, 6.5, 1.3$), 2.40-2.35 (*m*, 1H), 2.26-2.14 (*m*, 2H). ^{13}C NMR (101 MHz, MeOD) δ 168.16, 153.11, 151.22, 144.78, 138.41, 134.99, 133.92, 129.78, 129.43, 125.29, 90.39, 86.96, 85.87, 81.13, 47.38, 47.26, 39.44, 38.11. Analytical data for **19b** R_f 0.4 (10% methanol in DCM), HR-MS (NSI^+ , MeOH) for $\text{C}_{20}\text{H}_{21}\text{N}_3\text{O}_8\text{S}$. calc: 460.1285, found: 460.1273 ($\text{M} + \text{H}^+$) ^1H NMR (400 MHz, MeOD) δ 8.73 (*s*, 1H), 8.54 (*s*, 1H), 8.08 (*m*, 2H), 7.63 (*m*, 1H), 7.55 (*m*, 2H), 6.37 (*dd*, 1H, $J = 9.3, 5.9$), 5.66-5.58 (*m*, 1H), 4.38 (*dd*, 1H, $J = 6.9, 1.8$), 3.13 (*s*, 3H), 3.05 (*m*, 1H), 2.75 (*ddd*, 1H, $J = 13.0, 6.2, 1.3$), 2.63 (*dd*, 1H, $J = 13.8, 5.9$), 2.43 (*m*, 1H), 2.20 (*ddd*, 1H, $J = 14.1, 8.5, 7.0$), 2.10 (*dd*, 1H, $J = 13.0, 8.9$). ^{13}C NMR (101 MHz, MeOD) δ 168.15, 153.20, 151.22, 144.75, 138.43, 134.96, 133.89, 129.79, 129.75, 129.41, 125.56, 89.26, 86.34, 85.54, 81.11, 46.85, 46.41, 39.32, 38.16, 18.39.

(3'S, 6'S)-N6-Benzoyl-1-(2'-deoxy-, 6'-O-(methylsulfonyl)-3',5'-ethano- α - and - β -D-ribofuranosyl] cytosine **20a/b** A solution of **17a/b** (415 mg, 1.16 mmol) in pyridine (16 ml) was cooled to 0°C and MsCl (90 μl , 1.16 mmol) was added. The mixture was stirred overnight at 4°C. Sat. NaHCO_3 was added and the aqueous phase was extracted with ethyl acetate. The crude product **20a/b** precipitated in the organic phase and was used in the next experiment without further purification. R_f 0.49 (10% methanol in DCM), HR-MS (NSI^+ , THF) for $\text{C}_{19}\text{H}_{21}\text{N}_3\text{O}_7\text{S}$. Calc. 436.1173, found 436.1172 ($\text{M} + \text{H}^+$) ^1H NMR (400 MHz, DMSO) δ 11.21 (*br*, 2H), 8.23 (*m*, 2H), 8.00 (*m*, 4H), 7.62 (*m*, 2H), 7.51 (*m*, 4H), 7.37 (*m*, 2H), 6.11 (*dd*, 1H, $J = 9.3, 5.1$), 6.04 (*dd*, 1H, $J = 6.8, 2.7$), 5.68 (*s*, 1H), 5.53 (*s*, 1H), 5.20 (*m*, 1H), 5.10 (*m*, 1H), 4.67 (*dd*, 1H, $J = 6.9, 2.3$), 4.23 (*dd*, 1H, $J = 7.1, 1.9$), 3.23 (*s*, 3H), 3.21 (*s*, 3H), 2.63 (*dd*, 1H, $J = 14.5, 6.9$), 2.47 (*m*, 2H), 2.31 (*m*, 2H), 2.24 (*m*, 2H), 2.14 (*m*, 2H), 2.06 (*m*, 1H), 1.96 (*m*, 2H). ^{13}C NMR (101 MHz, DMSO) δ 162.99, 145.29, 133.20, 132.74, 132.65, 128.45, 128.40, 95.63, 89.25, 88.90, 87.29, 85.21, 83.76, 80.22, 79.86, 46.10, 45.99, 45.16, 45.10, 38.38, 37.71, 37.40, 21.01.

(3'S, 6'S)-1-(3'-O-Acetyl-2'-deoxy-6'-O-(methylsulfonyl)-3',5'-ethano- α - and - β -D-ribofuranosyl] thymine **21a/b** A solution of **18a/b** (250 mg, 0.72 mmol) in pyridine (7 ml) was cooled to 0°C and DMAP (9 mg, 0.07 mmol) and Ac_2O (0.08 ml, 0.8 mmol) were added. The mixture was stirred over night at r.t. and, after cooling to 0°C, carefully quenched and washed with sat. NaHCO_3 . The aqueous layers were extracted with DCM. The combined organic layers were dried over MgSO_4 and evaporated. FC (3% methanol in DCM) yielded **21a/b** (218 mg, 0.56 mmol, 78%) an anomeric ratio of α/β -1.25:1 as a white foam. R_f 0.49 (10% methanol in DCM), NSI^+ pos (MeCN) for $\text{C}_{15}\text{H}_{20}\text{N}_2\text{O}_8\text{S}$. Calc. 389.1013, found 389.1019 ($\text{M} + \text{H}^+$) ^1H NMR (400 MHz, CDCl_3) δ 7.24 (*m*, 1H), 7.06 (*m*, 1H), 6.11 (*t*, 1H, $J = 6.2$), 6.03 (*dd*, 1H, $J = 9.2, 5.6$), 5.24-5.15 (*m*, 2H), 4.95 (*dd*, 1H, $J = 6.2, 3.3$), 4.58 (*dd*, 1H, $J = 6.4, 1.4$), 3.05, 3.03 (2s, 6H), 2.92 (*dd*, 1H, $J = 14.8, 6.6$), 2.84 (*m*, 2H), 2.68 (*dd*, 1H, $J = 15.3, 6.0$), 2.54 (*m*, 2H), 2.48-2.29 (*m*, 5H), 2.14 (*m*, 1H), 2.09, 2.07 (2s, 6H), 1.97 (*m*, 3H), 1.96 (*m*, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 170.02, 163.14, 162.93, 149.91, 149.81, 134.92, 134.66, 111.82, 111.20, 90.48, 89.56, 86.93, 86.34, 84.73, 84.62, 79.91, 78.92, 77.33, 77.01, 76.69, 44.27, 43.96, 43.89, 43.79, 38.55, 38.46, 37.24, 21.05, 12.68, 12.63.

(3'S, 6'S)-N6-Acetyl-9-[3'-O-acetyl-2'-deoxy-6'-O-(methylsulfonyl)-3',5'-ethano- β -D-ribofuranosyl] -N6-benzoyladenine **22b** A solution of **19b** (195 mg, 0.42 mmol) in pyridine (12 ml) was cooled to 0°C and DMAP (5 mg, 42 μmol) and Ac_2O (0.12 ml, 1.3 mmol) were added. The mixture was stirred for 16 h at r.t. and, after cooling to 0°C, carefully quenched and washed with sat. NaHCO_3 . The aqueous layers were extracted with DCM. The combined organic layers were dried over MgSO_4 and evaporated. FC (5% methanol in DCM) yielded **22b** (192 mg, 0.38 mmol, 91%) as a white foam. R_f 0.8 (10% methanol in DCM), HR-MS (NSI^+ , EtOAc) for $\text{C}_{22}\text{H}_{23}\text{N}_5\text{O}_4\text{S}$. calc: 502.1391, found: 502.1385 ($\text{M} + \text{H}^+$). ^1H NMR (400 MHz, CDCl_3) δ 8.69 (*s*, 1H), 8.31 (*s*, 1H), 7.71 (*m*, 2H), 7.42 (*m*, 1H), 7.32 (*m*, 2H), 6.42 (*dd*, 1H, $J = 6.9, 2.9$), 5.18 (*m*, 1H) 4.90 (*dd*, 1H, $J = 6.1, 1.7$), 3.41 (*m*, 1H), 3.03 (*s*, 3H), 2.89 (*m*, 2H), 2.44 (*m*, 2H), 2.34 (*m*, 1H), 2.09 (*s*, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 175.38, 172.86, 172.05, 170.24, 152.94, 152.53, 152.43, 151.16, 134.41, 133.07, 129.44, 129.01, 128.78, 90.34, 87.23, 79.21, 44.41, 43.96, 38.65, 37.68, 25.61, 21.37.

(3'S, 6'S)-N6-Acetyl-1-[3'-O-acetyl-2'-deoxy-6'-O-(methylsulfonyl)-3',5'-ethano- α - and - β -D-ribofuranosyl] -N6-benzoylcytosine **23a/b** A solution of **20a/b** (769 mg, 1.76 mmol) in pyridine (35 ml) was cooled to 0°C and DMAP (22 mg, 0.18 mmol) and Ac_2O (0.5 ml, 5.28 mmol) were added. The mixture was stirred for 20 h at r.t. and, after cooling to 0°C, carefully quenched and washed with sat. NaHCO_3 . The aqueous layers were extracted with DCM. The combined organic layers were dried over MgSO_4 and evaporated. FC (5% methanol in DCM) yielded **23a/b** (628 mg, 1.3 mmol, 75% over two steps) in an anomeric ratio of α/β -2:1 as a white foam. R_f 0.9 (10% methanol in DCM), HR-MS (NSI^+ , EtOAc) for $\text{C}_{21}\text{H}_{23}\text{N}_5\text{O}_8\text{S}$. calc: 478.1279, found: 478.1268 ($\text{M} + \text{H}^+$), ^1H NMR (400 MHz, CDCl_3) δ 7.93 (*m*, 6H), 7.61 (*m*, 4H), 7.55 (*m*, 4H), 6.10 (*dd*, 1H, $J = 6.4, 4.1$), 6.04 (*dd*, 1H, $J = 8.5, 5.6$), 5.19 (*m*, 2H), 5.04 (*dd*, 1H, $J = 5.9, 3.7$), 4.69 (*d*, 1H), 3.15 (*m*, 1H), 3.04 (*s*, 3H), 3.03 (*s*, 3H), 2.99 (*m*, 1H), 2.83-2.67 (*m*, 3H), 2.50 (*m*, 2H), 2.35 (*m*, 4H), 2.08 (*m*, 6H), 2.04 (*m*, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 176.17, 170.32, 170.09, 163.25, 163.18, 154.73, 149.28, 144.01, 136.97, 133.47, 132.99, 129.09, 128.19, 97.45, 96.72, 90.54, 90.08, 89.53 ($\text{C}(1'')$), 88.09, 86.89, 85.77, 79.77, 79.31, 45.55, 45.11, 44.25, 43.74, 38.64, 38.61, 38.58, 37.66, 29.87, 29.53, 21.66, 21.53, 21.15.

(3'S, 6'R)-1-(3', 6'-Di-O-acetyl-2'-deoxy-3',5'-ethano- α - and - β -D-ribofuranosyl] thymine **24a/b** A solution containing **21a/b** (301 mg, 0.77 mmol) and CsOAc (2.1 g, 10.7 mmol) in DMSO (15 ml) was heated to 85°C and stirred for 16 h. After cooling to r.t. the mixture was diluted with ethyl acetate and washed with sat. NaHCO_3 . The combined organic layers were washed with H_2O and dried over MgSO_4 . Via FC (5% methanol in DCM) **24a/b** (254 mg, 0.72 mmol, 93%) an anomeric ratio of α/β -1.25:1 was obtained as a white foam. R_f 0.88 (10% methanol in DCM), HR-MS (NSI^+ , MeOH) for $\text{C}_{16}\text{H}_{20}\text{N}_2\text{O}_7$. Calc. 353.1343, found 353.1341 ($\text{M} + \text{H}^+$) ^1H NMR (400 MHz, CDCl_3) δ 7.36 (*m*, 1H), 7.30 (*m*, 1H), 6.41 (*t*, 1H, $J = 6.4$), 6.20 (*dd*, 1H, $J = 9.7, 5.2$), 5.43 (*m*, 1H), 5.27 (*m*, 1H), 4.94 (*dd*, 1H, $J = 6.8, 1.4$), 4.62 (*d*, 1H, $J = 6.8$), 2.98 (*m*, 1H), 2.84 (*dd*, 1H, $J = 14.3, 5.2$), 2.55 (*m*, 2H), 2.43 (*m*, 1H), 2.38 (*m*, 3H), 2.30 (*m*, 1H), 2.15 (*m*, 2H), 2.10, 2.09 (2s, 6H), 2.06-2.01 (*m*, 1H), 2.04, 2.03 (2s, 6H), 1.95 (*m*, 3H), 1.93 (*m*, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 170.51, 170.27, 169.74, 163.97, 163.70, 150.64, 150.52, 135.17, 134.65, 111.64, 111.37, 93.65, 93.53, 88.38, 87.53, 86.04, 83.88, 77.43, 77.28, 75.10, 45.15, 45.04, 44.65, 44.36, 42.85, 38.75, 37.50, 21.76, 21.64, 21.40, 12.86, 12.81.

(3'S, 6'R)-N6-Benzoyl-9-(3',6'-di-O-acetyl-2'-deoxy-3',5'-ethano- β -D-ribofuranosyl] adenine **25b** A solution containing **22b** (219 mg, 0.41 mmol) and CsOAc (1.1 g, 6 mmol) in DMSO (8 ml) was heated to 85°C and stirred for 16 h. After cooling to r.t. the mixture was diluted with ethyl acetate and washed with sat. NaHCO_3 . The combined organic layers were washed with H_2O and dried over MgSO_4 . FC purification (5% methanol in DCM) yielded **25b** (155 mg, 0.33 mmol, 81%) as a white foam. R_f 0.75 (10% methanol in DCM), HR-MS (NSI^+ , MeCN) for $\text{C}_{23}\text{H}_{23}\text{N}_5\text{O}_6$. calc: 466.1721, found: 466.1727 ($\text{M} + \text{H}^+$), ^1H NMR (400 MHz, CDCl_3) δ 9.11 (*br*, 1H), 8.77 (*s*, 1H), 8.28 (*s*, 1H), 8.03 (*m*, 2H), 7.60 (*m*, 1H), 7.52 (*m*, 2H), 6.61 (*dd*, 1H, $J = 6.8, 3.1$), 5.35 (*m*, 1H), 4.96 (*d*, 1H), 3.33 (*m*, 1H), 3.14 (*m*, 1H), 2.40 (*m*, 4H), 2.11 (*s*, 3H), 1.96 (*s*, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 170.38, 170.30, 152.85, 141.23, 141.15, 136.16, 133.04, 130.49, 129.06, 128.15, 94.17, 89.59, 86.63, 86.10, 85.24, 76.29, 45.24, 44.58, 38.61, 37.99, 29.90, 21.58, 21.48.

(3'S, 6'R)-N6-Benzoyl-1-(3', 6'-Di-O-acetyl-2'-deoxy-3',5'-ethano- α - and - β -D-ribofuranosyl] cytosine **26a/b** A solution containing **23a/b** (523 mg, 1.09 mmol) and CsOAc (2.9 g, 15.1 mmol) in DMSO (20 ml) was heated to 85°C and stirred for 16 h. After cooling to r.t. the mixture was diluted with ethyl acetate and washed with sat. NaHCO_3 . The combined organic layers were washed with H_2O and dried over MgSO_4 . The crude product **26a/b** was used for the following step without purification. R_f 0.82 (10% methanol in DCM), HR-MS (NSI^+ , EtOAc) for $\text{C}_{22}\text{H}_{23}\text{N}_5\text{O}_7$. calc: 442.1609, found: 442.1601 ($\text{M} + \text{H}^+$)

(3'S, 6'R)-1-(2'-Deoxy-3',5'-ethano- α - and - β -D-ribofuranosyl] thymine **27a/b** The nucleoside **24a/b** (254 mg, 0.72 mmol) was dissolved in 0.2 M NaOH in 5:4:1 THF/methanol/ H_2O (40 ml) at 0°C: The solution was stirred for one hour at 0°C and quenched by the addition of ammonium chloride. The solvents were then evaporated and the remains absorbed on silica gel. Purification by FC (10% methanol in DCM) yielded compound **27a/b** (123 mg, 0.45 mmol, 64%) in anomeric ratio of α/β -1.25:1 as a white foam. R_f 0.2 (10% methanol in DCM), HR-MS (NSI^+ , MeOH) for $\text{C}_{12}\text{H}_{16}\text{N}_2\text{O}_5$. Calc. 268.0951, found 268.0955 (M^+), ^1H NMR (400 MHz, DMSO) δ 11.25 (*br*, 2H), 7.76 (*s*, 1H), 7.66 (*s*, 1H), 6.20 (*m*, 2H), 5.31 (*s*, 1H), 5.26 (*s*, 1H), 4.94 (*d*, 1H, $J = 2.7$), 4.71 (*d*, 1H, $J = 3.8$), 4.39 (*dd*, 1H, $J = 7.1, 3.0$), 4.31 (*m*, 1H), 4.23 (*m*, 1H), 4.08 (*m*, 1H), 2.62 (*dd*, 1H, $J = 13.7, 6.9$), 2.31 (*m*, 1H), 2.22 (*m*, 1H), 2.15 (*m*, 1H), 2.09 (*m*, 1H), 2.02 (*m*, 2H) 1.95(*m*, 1H), 1.85 (*m*, 1H), 1.80 (*m*, 3H), 1.76 (*m*, 3H), 1.77 (*m*, 2H), 1.55 (*m*, 1H). ^{13}C NMR (101 MHz, DMSO) δ 163.79, 163.63, 150.40, 150.36, 136.50, 109.57, 109.13, 90.11, 89.98, 86.81, 86.10, 85.59, 83.66, 72.36, 70.90, 48.33, 47.92, 46.80, 46.02, 41.32, 40.66, 12.34, 12.25.

(3'S, 6'R)-N6-Benzoyl-9-(2'-deoxy-3',5'-ethano- β -D-ribofuranosyl] adenine **28b** The nucleoside **25b** (115 mg, 0.25 mmol) was dissolved in 0.2 M NaOH in 5:4:1 THF/methanol/ H_2O (17 ml) at 0°C: The solution was stirred for one hour at 0°C and quenched by the addition of ammonium chloride. The solvents were then evaporated and the remains absorbed on silica gel. Purification by FC (10% methanol in DCM) yielded compound **28b** (80 mg, 0.21 mmol, 84%) as a white foam. R_f 0.3 (10% methanol in DCM), HR-MS (NSI^+ , MeOH) for $\text{C}_{19}\text{H}_{19}\text{N}_5\text{O}_4$. calc: 382.1510, found: 382.1505 ($\text{M} + \text{H}^+$), ^1H NMR (300 MHz, MeOD) δ 8.71 (*s*, 1H), 8.65 (*s*, 1H), 8.09 (*m*, 2H), 7.65 (*m*, 1H), 7.55 (*m*, 1H), 6.55 (*dd*, 1H, $J = 9.3, 5.9$), 4.50 (*m*, 1H), 4.38 (*dd*, $J = 6.9, 1.4$, 1H), 3.01 (*dd*, 1H, $J = 13.5, 9.4$), 2.70 (*dd*, 1H, $J = 13.6, 5.9$), 2.33-2.24 (*m*, 2H), 2.03 (*m*, 2H). ^{13}C NMR (75 MHz, MeOD) δ 153.22, 153.09, 151.14, 144.27, 134.98, 133.90, 129.76, 129.42, 125.05, 92.42, 88.68, 85.90, 74.93, 54.79, 49.46, 41.83.

(3'S, 6'R)-N6-Benzoyl-1-(2'-deoxy-3',5'-ethano- α - and - β -D-ribofuranosyl] cytosine **29a/b** The nucleoside **26a/b** (386 mg, 0.87 mmol) was dissolved in 0.2 M NaOH in 5:4:1 THF/methanol/ H_2O (50 ml) at 0°C: The solution was stirred for one hour at 0°C and quenched by the addition of ammonium chloride. The solvents were then evaporated and the remains absorbed on silica gel. Purification by FC (5% methanol in DCM) yielded compound **29a/b** (183 mg, 0.51 mmol, 59% over two steps) in an anomeric ratio of α/β -2:1 as a white foam. R_f 0.43 (10% methanol in DCM), HR-MS (NSI^+ , MeOH) for $\text{C}_{18}\text{H}_{19}\text{N}_5\text{O}_3$. calc: 380.1217, found: 380.1220 ($\text{M} + \text{Na}^+$), ^1H NMR (400 MHz, MeOD) δ 8.46 (*d*, 1H, $J = 7.5$), 8.28 (*d*, 1H, $J = 7.5$), 7.98 (*m*, 4H), 7.63 (*m*,

4H), 7.54 (m, 4H), 6.33 (dd, 1H, *J* = 8.9, 5.8), 6.21 (dd, 1H, *J* = 6.8, 3.2), 4.68 (dd, 1H, *J* = 7.2, 3.1), 4.49 (m, 1H), 4.43 (m, 1H), 4.35 (d, 1H), 3.03 (dd, 1H, *J* = 14.4, 6.8), 2.67 (dd, 1H, *J* = 13.6, 5.8), 2.37 (m, 3H), 2.24 (m, 1H), 2.15 (m, 1H), 2.09 (m, 2H), 2.04 (m, 1H), 1.94 (m, 1H), 1.85 (m, 1H). ¹³C NMR (101 MHz, MeOD) δ 169.13, 164.79, 157.92, 146.88, 146.56, 134.76, 134.72, 134.10, 134.06, 129.83, 129.17, 129.13, 98.76, 98.06, 93.64, 92.52, 92.07, 88.92, 88.10, 87.97, 74.88, 73.43, 50.01, 48.88, 42.27, 41.63.

(3'S, 6'R)-1-[2'-Deoxy-6'-O-[(4,4'-dimethoxytriphenyl)methyl]-3',5'-ethano- α - and - β -D-ribofuranosyl] thymine (**30a**, **30b**) To a solution of nucleoside **27a/b** (456 mg, 1.7 mmol) in pyridine (8 ml) was added DMT-Cl (1.7 g 5.1 mmol) in three portions and it was stirred for 24 h at r.t. The solution was then diluted with ethyl acetate, washed with sat. NaHCO₃ and dried over MgSO₄. Purification by FC (2.5% methanol in DCM) yielded the corresponding anomers α and β , **30a** (470 mg, 0.82 mmol, 48%) and **30b** (384 mg, 0.67 mmol, 40%) resp., as pale yellow foams. Analytical data of **30a**: R_f 0.23 (3% methanol in DCM), HR-MS (ESI⁺, MeCN) for C₃₃H₃₄N₂O₇. Calc. 593.2258, found 593.2250 (M + Na⁺), ¹H NMR (400 MHz, CDCl₃) δ 7.47 (m, 2H), 7.35 (m, 4H), 7.29 (m, 2H), 7.22 (m, 2H), 6.83 (m, 4H), 5.95 (dd, 1H, *J* = 7.8, 3.7), 4.40 (dd, 1H, *J* = 7.0, 3.1), 4.24 (m, 1H), 3.79 (s, 6H), 2.89 (dd, 1H, *J* = 14.5, 7.8), 2.30 (dd, 1H, *J* = 14.5, 3.7), 1.95 (m, 1H), 1.91 (m, 3H), 1.67 (m, 1H), 1.53 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 163.87, 158.81, 150.59, 145.86, 138.45, 137.10, 136.98, 130.28, 130.25, 128.28, 128.16, 127.04, 113.49, 110.80, 91.87, 91.50, 87.46, 87.22, 75.18, 55.45, 47.22, 46.53, 46.39, 40.46, 12.63, 11.67. Analytical data of **30b**, R_f 0.17 (3% methanol in DCM), HR-MS (ESI⁺, MeCN) for C₃₃H₃₄N₂O₇. Calc. 593.2258, found 593.2251 (M + Na⁺), ¹H NMR (400 MHz, CDCl₃) δ 8.69 (br, 1H), 7.45 (m, 2H), 7.35 (m, 4H), 7.32 (m, 1H), 7.27 (m, 2H), 7.21 (m, 1H), 6.82 (m, 4H), 6.27 (dd, 1H, *J* = 8.8, 5.9), 4.33 (m, 1H), 4.05 (dd, 1H, *J* = 7.5, 2.1), 3.78 (s, 6H), 2.49 (m, 2H), 2.10 (m, 1H), 1.77 (m, 2H), 1.50 (m, 3H), 1.18 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 163.72, 158.91, 158.89, 150.54, 145.65, 136.86, 136.66, 135.61, 130.22, 130.15, 128.34, 128.18, 127.18, 113.67, 111.57, 89.85, 88.10, 87.68, 85.01, 76.40, 55.47, 46.99, 46.62, 46.08, 39.32, 12.31.

(3'S, 6'R)-N6-Benzoyl-9-[2'-Deoxy-6'-O-[4,4'-(dimethoxytriphenyl)methyl]-3',5'-ethano- β -D-ribofuranosyl] adenine **31b** To a solution of nucleoside **28b** (80 mg, 0.21 mmol) in pyridine (2 ml) was added DMT-Cl (213 mg 0.63 mmol) in three portions and the mixture was stirred for 24 h at r.t. The solution was then diluted with ethyl acetate, washed with sat. NaHCO₃ and dried over MgSO₄. Purification by FC (5% methanol in DCM) yielded compound **31b** (129 mg, 0.19 mmol, 90%) as a white foam. R_f 0.42 (10% methanol in DCM), HR-MS (ESI⁺, MeOH) for C₄₀H₃₇N₅O₆. calc: 684.2817, found: 684.2830 (M + H⁺), ¹H NMR (400 MHz, CDCl₃) δ 8.81 (s, 1H), 8.27 (s, 1H), 8.04 (m, 2H), 7.61 (m, 1H), 7.53 (m, 2H), 7.45 (m, 2H), 7.35 (m, 4H), 7.28 (m, 2H), 7.22 (m, 1H), 6.81 (m, 4H), 6.46 (dd, 1H, *J* = 9.1, 5.4), 4.35 (m, 1H), 4.21 (dd, 1H, *J* = 7.4, 3.5), 3.78 (s, 6H), 2.92 (dd, 1H, *J* = 13.2, 9.2), 2.64 (dd, 1H, *J* = 13.2, 5.5), 2.02 (m, 1H), 1.83-1.58 (m, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 171.37, 171.24, 158.84, 153.04, 150.05, 149.74, 145.65, 141.30, 136.90, 136.87, 136.18, 132.97, 130.25, 129.09, 128.28, 128.23, 128.11, 127.14, 123.95, 113.57, 90.02, 87.58, 87.17, 85.18, 77.43, 75.85, 55.46, 47.26, 46.60, 46.08, 39.91.

(3'S, 6'R)-N6-Benzoyl-1-[2'-Deoxy-6'-O-[4,4'-(dimethoxytriphenyl)methyl]-3',5'-ethano- α - and - β -D-ribofuranosyl] cytosine (**32a**, **32b**) To a solution of nucleoside **29a/b** (394 mg, 1.1 mmol) in pyridine (6 ml) was added DMT-Cl (1.1 g 3.3 mmol) in three portions and it was stirred for 24 h at r.t. The solution was then diluted with ethyl acetate, washed with sat. NaHCO₃ and dried over MgSO₄. Purification by FC (ethyl acetate/hexane 4:1 to 5% methanol in DCM) yielded the corresponding anomers α and β , **32a** (450 mg, 0.68 mmol, 62%) and **32b** (217 mg, 0.33 mmol, 30%) as white foams. Analytical data for **32a**: R_f 0.22 (ethyl acetate/hexane 4:1), HR-MS (ESI⁺, MeCN) for C₃₉H₃₇N₃O₇. Calc: 660.2704, found: 660.2724 (M + H⁺), ¹H NMR (400 MHz, CDCl₃) δ 9.00 (br, 1H), 7.87 (m, 3H), 7.55 (m, 1H), 7.46 (m, 5H), 7.36 (m, 4H), 7.26 (m, 2H), 7.21 (m, 1H), 6.83 (m, 4H), 6.05 (dd, 1H, *J* = 7.1, 2.1), 4.48 (dd, 1H, *J* = 7.3, 3.8), 4.25 (m, 1H), 3.79 (s, 6H), 3.03 (dd, 1H), 2.64 (dd, 1H, *J* = 14.8, 2.0), 1.64 (m, 3H). ¹³C NMR (101 MHz,) δ 162.60, 158.72, 155.27, 146.01, 145.82, 137.07, 137.03, 133.27, 133.14, 130.26, 129.08, 128.32, 128.10, 127.87, 126.98, 113.43, 96.20, 93.05, 92.81, 87.17, 86.83, 75.04, 60.59, 55.40, 47.40, 46.27, 40.51, 21.22, 14.37. Analytical data for **32b**: R_f 0.05 (ethyl acetate/hexane 4:1), HR-MS (ESI⁺, MeCN) for C₃₉H₃₇N₃O₇. Calc: 660.2704, found: 660.2704 (M + H⁺), ¹H NMR (300 MHz, CDCl₃) δ 8.77 (br, 1H), 8.23 (m, 1H), 7.89 (m, 2H), 7.60 (m, 1H), 7.51 (m, 4H), 7.37-7.19 (m, 8H), 6.84 (m, 4H), 6.45 (dd, 1H, *J* = 8.6, 5.5), 4.37 (m, 1H), 4.23 (d, 1H, *J* = 5.8), 3.79, 3.77 (2s, 6H), 2.84 (dd, 1H, *J* = 13.5, 5.4), 2.36 (dd, 1H, *J* = 13.5, 8.7), 1.88-1.73 (m, 3H), 1.42 (m, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 158.87, 158.37, 145.45, 136.83, 136.71, 133.38, 130.28, 130.20, 129.26, 128.31, 127.76, 127.17, 113.62, 113.51, 90.84, 89.31, 88.06, 87.68, 87.12, 76.79, 55.43, 55.42, 47.10, 39.46.

(3'S, 6'R)-1-[6'-O-[(2-Cyanoethoxy)(diisopropylamino)phosphino]-2'-deoxy-6'-O-[(4,4'-dimethoxytriphenyl)methyl]-3',5'-ethano- β -D-ribofuranosyl] thymine **33b** Compound **30b** (163 mg, 0.29 mmol) was dissolved in MeCN (2.5 ml) and Hünig's base (0.24 ml, 1.43 mmol) and Cep-Cl (0.19 ml, 0.87 mmol) were added. The solution was stirred at r.t. for 1 h, diluted with ethyl acetate and washed with sat. NaHCO₃. The aqueous layer is extracted with ethyl acetate and dried over MgSO₄. Purification by FC (ethyl acetate/hexane 1:1) yielded phosphoramidite **33b** (214 mg, 0.24 mmol, 72%) as a white foam. ³¹P-NMR showed no phosphonate peak, therefore no further purification was

necessary. R_f 0.63 (ethyl acetate/hexane 2:1), HR-MS (ESI⁺, MeCN) for C₄₂H₅₁N₄O₈P. Calc. 771.3517, found 771.3531 (M + H⁺), ¹H NMR (400 MHz, CDCl₃) δ 8.11 (br, 1H), 7.45 (m, 2H), 7.35 (m, 4H), 7.27 (m, 4H), 7.20 (m, 1H), 6.82 (m, 4H), 6.23 (dd, 1H, *J* = 9.6, 4.9), 4.33 (m, 1H), 4.27 (dd, 1H, *J* = 14.8, 7.5), 3.79 (m, 6H), 3.80-3.55 (m, 4H), 2.85 (m, 1H), 2.64 (m, 1H), 2.58 (t, 1H, *J* = 6.3), 2.52 (m, 1H), 2.19 (m, 2H), 1.70 (m, 1H), 1.50 (m, 3H), 1.16 (m, 9H), 1.10 (m, 3H), 1.05 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 163.59, 158.89, 150.19, 145.61, 136.87, 136.59, 135.70, 130.24, 130.14, 128.35, 128.19, 127.18, 113.69, 111.30, 91.69, 89.46, 88.19, 85.18, 77.44, 76.32, 76.20, 60.62, 58.17, 57.99, 55.47, 43.66, 43.51, 38.94, 38.85, 24.76, 24.53, 24.45, 20.56, 14.41, 12.30, 12.26. ³¹P NMR (122 MHz, CDCl₃) δ 142.13, 141.81.

(3'S, 6'R)-N6-Benzoyl-9-[3'-O-[(2-cyanoethoxy)(diisopropylamino)phosphino]-2'-deoxy-6'-O-[4,4'-dimethoxytriphenyl)methyl]-3',5'-ethano- β -D-ribofuranosyl] adenine **34b** Compound **31b** (290 ng, 0.42 mmol) was dissolved in MeCN (4 ml) and Hünig's base (0.36 ml, 2.1 mmol) and Cep-Cl (0.28 ml, 1.3 mmol) were added. The solution was stirred at r.t. for 1 h, diluted with ethyl acetate and washed with sat. NaHCO₃. The aqueous layer was extracted with ethyl acetate and the organic layers dried over MgSO₄. Purification by FC (ethyl acetate/hexane 1:1) yielded phosphoramidite **34b** (310 mg, 0.35 mmol, 83%) as a white foam. ³¹P-NMR showed a H-phosphonate peak. Compound **34b** had therefore to be further purified. **34b** was dissolved in 1 ml of DCM and added dropwise to icecold hexane. The filter cake is collected by washing the filter with DCM and evaporate the solvent. ³¹P-NMR showed no more phosphonate so the pure phosphoramidite **34b** (325 mg, 0.37 mmol, 87%) could be collected. R_f 0.48 (ethyl acetate/hexane 2:1), HR-MS (ESI⁺, MeCN) for C₄₉H₅₄N₇O₇P. calc: 884.3901, found: 884.3902 (M + H⁺), ¹H NMR (300 MHz, CDCl₃) δ 9.07 (s, 1H), 8.83 (d, 1H, *J* = 3.2), 8.26 (s, 1H), 8.04 (m, 2H), 7.61 (m, 1H), 7.55 (m, 2H), 7.46 (m, 2H), 7.36 (m, 4H), 7.32 (m, 2H), 6.82 (m, 4H), 6.45 (m, 1H), 4.36 (m, 2H), 3.78 (s, 6H), 3.74-3.54 (m, 4H), 3.05 (m, 2H), 2.63 (t, 1H, *J* = 6.3), 2.55 (t, 1H, *J* = 6.3), 2.08 (m, 1H), 1.90 (m, 2H), 1.50 (m, 1H), 1.16 (m, 9H), 1.10 (d, *J* = 6.8, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 164.71, 158.73, 153.02, 151.71, 145.59, 141.41, 141.28, 136.85, 136.80, 134.02, 132.86, 130.21, 130.16, 129.02, 128.22, 128.15, 128.00, 127.02, 123.21, 117.78, 117.72, 113.49, 91.16, 91.07, 91.04, 90.95, 89.89, 89.71, 89.68, 89.64, 87.60, 87.55, 85.26, 85.11, 77.36, 75.67, 75.53, 58.11, 58.03, 57.93, 57.85, 55.38, 45.48, 45.40, 45.12, 43.60, 43.56, 43.48, 43.43, 39.35, 39.32, 24.73, 24.67, 24.50, 24.47, 24.39, 20.56, 20.48, 20.40. ³¹P NMR (122 MHz, CDCl₃) δ 142.13, 142.07.

(3'S, 6'R)-N6-Benzoyl-1-[3'-O-[(2-cyanoethoxy)(diisopropylamino)phosphino]-2'-deoxy-6'-O-[4,4'-dimethoxytriphenyl)methyl]-3',5'-ethano- β -D-ribofuranosyl] cytosine **35b** Compound **32b** (216 mg, 0.33 mmol) was dissolved in MeCN (3 ml) and Hünig's base (0.28 ml, 1.6 mmol) and Cep-Cl (0.22 ml, 0.99 mmol) were added. The solution was stirred at r.t. for 2 h, diluted with ethyl acetate and washed with sat. NaHCO₃. The aqueous layer was extracted with ethyl acetate and dried over MgSO₄. Purification by FC (ethyl acetate/hexane 1:1) yielded phosphoramidite **35b** (214 mg, 0.24 mmol, 72%) as a white foam. ³¹P-NMR showed a phosphonate peak. Compound **35b** had therefore to be further purified. **35b** was dissolved in 1 ml of DCM and added dropwise to icecold hexane. The filter cake is collected by washing the filter with DCM and evaporate the DCM. After three cycles and another FC ³¹P-NMR showed no more phosphonate so the pure phosphoramidite **35b** could be collected. R_f 0.4 (ethyl acetate/hexane 2:1), HR-MS (ESI⁺, THF) for C₄₈H₅₄N₅O₈P. calc: 860.3788, found: 860.3789 (M + H⁺), ¹H NMR (400 MHz, CDCl₃) δ 8.70 (br, 1H), 8.20 (m, 1H), 7.90 (m, 2H), 7.62 (m, 1H), 7.52 (m, 2H), 7.44 (m, 2H), 7.33 (m, 5H), 7.25 (m, 3H), 6.84 (m, 4H), 6.24 (m, 1H), 4.40 (m, 2H), 3.78 (2s, 6H), 3.77-3.53 (m, 4H), 3.11 (dd, 1H, 13.9, 4.7), 2.65 (t, 1H, *J* = 6.3), 2.57 (t, 1H, *J* = 6.4), 2.38 (m, 1H), 2.09 (m, 1H), 1.85 (m, 1H), 1.81 (m, 1H), 1.44 (m, 1H) 1.15 (m, 9H), 1.08 (m, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 162.21, 158.87, 158.84, 145.37, 136.79, 136.63, 133.33, 130.26, 130.16, 129.25, 128.32, 127.75, 127.17, 113.63, 91.68, 91.59, 91.52, 91.43, 90.40, 90.34, 90.17, 90.10, 88.12, 88.09, 87.38, 87.34, 77.43, 76.44, 76.43, 58.25, 58.08, 58.00, 55.48, 55.42, 46.98, 46.96, 46.74, 46.64, 46.56, 46.33, 46.25, 45.79, 45.68, 43.64, 43.51, 39.09, 24.79, 24.72, 24.53, 24.47, 24.40, 24.21, 24.13, 24.10, 22.54, 20.54, 20.50, 20.46, 20.42, 14.41, 14.33. ³¹P NMR (122 MHz, CDCl₃) δ 149.96, 149.68.

(3R, 5S, 7S)-3-methoxyoctahydopentalene-7,5-diol **36b** The sugar **10b** (1.0 g, 3.6 mmol) was dissolved in 0.2 M NaOH in 5:4:1 THF/methanol/H₂O (150 ml) at 0°C. The solution was stirred for one hour at 0°C and quenched by the addition of ammonium chloride. The solvents were then evaporated and the remains absorbed on silica gel. Purification by FC (5% methanol in DCM) yielded compound **36b** (618 mg, 3.5 mmol, 97%) as a colorless oil. R_f 0.14 (ethyl acetate/hexane 1:1), HR-MS (ESI⁺, MeOH) δ C₈H₁₄O₄. Calc. 197.0784, found 197.0788 (M + Na⁺), ¹H NMR (300 MHz, MeOD) δ 4.98 (dd, 1H, *J* = 5.8, 2.0), 4.40 (m, 1H), 4.23 (dd, 1H, *J* = 6.7, 2.3), 3.27 (s, 3H), 2.27 (m, 2H), 2.00 (m, 1H), 1.94 (m, 1H), 1.85 (m, 1H), 1.74 (dd, 1H, *J* = 13.0, 7.9). ¹³C NMR (75 MHz, MeOD) δ 107.38, 90.61, 86.83, 72.44, 55.27, 49.70, 48.90, 42.88.

tert-butyl(((3R,5S,7S)-3-methoxy-7-(((2,3,3-trimethylbutan-2-yl)silyl)oxy)octahydopentalen-3a-yl)oxy)dimethylsilane **37b** Compound **36b** (1.7 g, 10.0 mmol) was dissolved in DMF (40 ml). TBSCl (3.8 g, 25.0 mmol) and imidazole (2.1 g, 30.0 mmol) were added and the mixture was stirred at 85°C for 2 d. The solution was then diluted with ethyl acetate, washed with brine and H₂O and dried over MgSO₄. Purification by FC (ethyl acetate/hexane 3:1) yielded **46** (3.3 g, 8.2 mmol, 82%) as a colorless oil. R_f 0.9 (ethyl acetate/hexane 1:1), HR-MS (ESI⁺, THF) for C₂₀H₄₂O₄Si₂.

Calc. 403.2694, found 403.2693 (M + H⁺). ¹H NMR (300 MHz, CDCl₃) δ 4.99 (dd, 1H, J = 5.7, 2.2), 4.49 (m, 1H), 4.25 (d, 1H, J = 6.4), 3.33 (s, 3H), 2.33 (m, 2H), 2.00 (m, 2H), 1.77 (m, 2H), 0.88 (m, 18H), 0.08 (m, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 105.87 (C(3)), 89.93 (C(1)), 71.85 (C(7)), 55.13 (OMe), 50.60 (C(4)), 49.47 (C(6)), 41.98 (C(8)), 26.08 (TBS), 25.89 (TBS), 18.42 (TBS), 17.99 (TBS), -2.50 (TBS), -2.55 (TBS).

(3'S, 6'S)- 2-amino-6-chloro-9-{3', 6'-di-O-[(*tert*-butyl)-dimethylsilyl]-2'-deoxy-3',5'-ethano-α- and -β-D-ribofuranosyl} purine **38a/b** To a suspension of 2'-amino-6'-chloropurine (814 mg, 4.8 mmol) in MeCN (11 ml) was added BSA (2.3 ml, 9.6 mmol). The mixture was stirred at r.t. until a clear solution appeared. Compound 46 (858 mg, 2.1 mmol, in 5 ml MeCN) and TMSOTf (0.13 ml, 0.72 mmol) was then added and the mixture was stirred for 6 h at 55°C. The brownish solution was diluted by the addition of ethyl acetate, washed with sat. NaHCO₃ and dried over MgSO₄. Purification by FC (ethyl acetate/hexane 1:3) yielded **38b** (411 mg, 0.76 mmol, 36%) and **38a** (316 mg, 0.58 mmol, 28%) as white foams. Analytical data of **38b**: R_f 0.4 (hexane/ethyl acetate 3:1), HR-MS (ESI⁺, EtOAc) for C₂₄H₄₃N₅O₅ClSi₂. Calc: 540.2587, found: 540.2608 (M + H⁺). ¹H NMR (400 MHz, CDCl₃) δ 7.87 (s, 1H), 6.00 (dd, 1H, J = 9.1, 5.6), 5.13 (br, 2H), 4.40 (m, 1H), 4.31 (d, 1H, J = 6.3), 2.54 (m, 2H), 2.34 (m, 1H), 2.12 (m, 1H), 1.84 (m, 2H), 0.90 (m, 18H), 0.16 (m, 6H), 0.08 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 159.18, 153.72, 151.77, 140.60, 126.19, 89.88, 86.42, 83.86, 71.80, 48.95, 47.24, 40.71, 26.05, 25.87, 18.33, 18.03, -2.37, -2.45, -4.42, -4.48. Analytical data of **38a**: R_f 0.26 (hexane/ethyl acetate 3:1), HR-MS (ESI⁺, EtOAc) for C₂₄H₄₃N₅O₅ClSi₂. Calc: 540.2587, found: 540.2607 (M + H⁺). ¹H NMR (400 MHz, CDCl₃) δ 8.19 (s, 1H), 6.24 (dd, 1H, J = 7.1, 1.6), 5.11 (br, 2H), 4.45 (d, 1H, J = 6.1), 4.25 (m, 1H), 2.85 (dd, 1H, J = 14.6, 1.5), 2.48 (dd, 1H, J = 14.6, 1.5), 2.30 (m, 1H), 2.12 (m, 1H), 1.90 (m, 1H), 1.81 (m, 1H), 0.89, 0.80 (2s, 18H₃), 0.12 (s, 3H), 0.07 (s, 6H), 0.02 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 159.15, 153.63, 151.52, 141.11, 125.92, 91.16, 86.93, 84.80, 71.49, 50.35, 48.48, 40.79, 26.04, 25.79, 18.31, 17.97, -2.26, -2.55, -4.47, -4.56.

(3'S, 6'S)- 3'-9-{3',6'-di-O-[(*tert*-butyl)-dimethylsilyl]-2'-deoxy-3',5'-ethano-α- and -β-D-ribofuranosyl} guanine **39a/b** To a solution of 3-hydroxypropionitrile (0.4 ml, 5.9 mmol) in THF (8 ml) at 0°C was carefully added NaH (60%, 285 mg, 7.1 mmol) and the suspension was stirred for 1 h at r.t. The anomeric compound **38a/b** (700 mg, 1.3 mmol in 8 ml THF) was added and the brown mixture was stirred for another 3 h at r.t. Addition of silica, evaporation of the solvents and filtration (10% methanol in DCM) over a patch of silica yielded the crude product **39a/b**. The brown foam was used without further purification in the next step. R_f 0.5 (10% methanol in DCM), HR-MS (ESI⁺, MeCN) for C₂₄H₄₃N₅O₄Si₂. Calc: 521.81, found 522.29 (M + H⁺)

(3'S, 6'S)- N2-[N,N-Dimethylformamidino]-9-{3',6'-di-O-[(*tert*-butyl)-dimethylsilyl]-2'-deoxy-3',5'-ethano-α- and -β-D-ribofuranosyl} guanine **40a/b** The crude compound **39a/b** (750 mg, ~1.4 mmol) was dissolved in DMF (12 ml) and N,N-dimethylformamide dimethyl acetate (0.37 ml, 2.8 mmol) was added. The clear yellow solution was stirred for 2 h at 55°C. The solvent was evaporated via Kugelrohr distillation and purified by FC (5% methanol in DCM) to obtain nucleoside **40a/b** (715 mg, 1.2 mmol, 71% over 2 steps) in an anomeric ratio of α/β=2:1 as yellow oil. R_f 0.5 (10% methanol in DCM), HR-MS (ESI⁺, EtOAc) for C₂₇H₄₉N₆O₄Si₂. Calc: 577.3348, found: 577.3339 (M + H⁺). ¹H NMR (300 MHz, MeOD) δ 8.66 (s, 1H), 8.62 (s, 1H), 8.01 (2s, 2H), 6.25 (dd, 1H, J = 6.8, 1.7), 6.14 (dd, 1H, J = 9.6, 5.1), 4.57 (d, 1H, J = 6.1), 4.45 (m, 1H), 4.34 (m, 2H), 3.20 (m, 6H), 3.12 (m, 6H), 2.99 (s, 1H), 2.86 (m, 2H), 2.64-2.36 (m, 5H), 2.12 (m, 2H), 1.85 (m, 4H), 0.96 (s, 18H), 0.92 (2s, 18H), 0.77 (m, 12H), 0.21 (m, 12H). ¹³C NMR (75 MHz, CDCl₃) δ 158.38, 158.28, 158.22, 157.10, 156.90, 150.37, 135.72, 118.34, 120.54, 90.85, 89.89, 87.00, 86.54, 84.23, 82.88, 77.43, 71.95, 71.65, 58.07, 48.82, 48.72, 41.56, 40.80, 35.43, 26.02, 25.90, 25.83, 21.70, 18.27, 18.06, 18.00, -2.29, -2.46, -2.52, -4.47, -4.54.

(3'S, 6'S)- N2-[N,N-Dimethylformamidino]-9-{3'-O-[(*tert*-butyl)-dimethylsilyl]-2'-deoxy-3',5'-ethano-α- and -β-D-ribofuranosyl} guanine **41a/b** A solution of **40a/b** (1.5 g, 2.6 mmol) in THF (20 ml) was cooled to 0°C. HF/Et₃N (37% HF, 1.7 ml, 3.9 mmol) was added and allowed to warm to r.t. The reaction mixture was stirred at r.t. over night and then quenched with silica. The solvent was evaporated and the crude mixture purified by FC (5% methanol in DCM). **41a/b** (658 mg, 1.4 mmol, 55%) in an anomeric ratio of α/β=2:1 was obtained as a white foam. R_f 0.5 (10% methanol in DCM), HR-MS (ESI⁺, MeCN) for C₂₁H₃₄N₆O₄Si. Calc: 463.2484, found: 463.2472 (M + H⁺). ¹H NMR (400 MHz, MeOD) δ 8.66 (s, 1H), 8.62 (s, 1H), 8.01 (s, 1H), 7.97 (s, 1H), 6.24 (dd, 1H, J = 6.7, 1.6), 6.09 (dd, 1H, J = 10.0, 5.1), 4.59 (m, 1H), 4.53 (m, 1H), 4.30 (m, 1H), 4.25 (m, 1H), 3.21 (m, 6H), 3.12 (m, 6H), 2.92 (dd, 1H, J = 14.6, 1.6), 2.71 (m, 1H), 2.60 (m, 2H), 2.49 (m, 1H), 2.41 (m, 1H), 2.15 (m, 2H), 1.89-1.79 (m, 4H), 0.95 (s, 9H), 0.76 (s, 9H), 0.22 (m, 6H), 0.12 (s, 3H), -0.02 (s, 3H). ¹³C NMR (101 MHz, MeOD) δ 160.16, 159.69, 159.62, 159.00, 158.85, 151.96, 151.43, 138.82, 138.31, 121.07, 120.95, 92.76, 91.03, 88.52, 88.12, 87.23, 84.98, 71.63, 71.39, 50.21, 47.74, 41.62, 41.45, 41.18, 40.91, 35.34, 26.24, 26.07, 18.73, 18.56, -2.41, -2.45, -2.48, -2.75.

(3'S, 6'S)- N2-[N,N-Dimethylformamidino]-9-{6'-O-(methylsulfonyl)-3'-O-[(*tert*-butyl)-dimethylsilyl]-2'-deoxy-3',5'-ethano-α- and -β-D-ribofuranosyl} guanine **42a/b** A solution of **41a/b** (243 mg, 0.53 mmol) in pyridine (5.5 ml) was cooled to 0°C and MsCl (40 μl, 0.58 mmol) was added. The mixture was stirred for 4 h at r.t. After the addition of silica the pyridine was evaporated and the crude product purified by FC (5%

methanol in DCM). Compound **42a/b** (263 mg, 0.49 mmol, 92%) in an anomeric ratio of α/β=2:1 was obtained as a white solid. R_f 0.4 (10% methanol in DCM), HR-MS (ESI⁺, EtOAc) for C₂₂H₃₆N₆O₆SSi. Calc: 540.2186, found: 541.2183 (M⁺). ¹H NMR (400 MHz, CDCl₃) δ 8.62 (s, 1H, N=CHN(CH₃)₂), 8.53 (s, 1H), 7.93 (s, 1H), 7.79 (s, 1H), 6.24 (dd, 1H, J = 7.1, 3.7), 6.04 (dd, 1H, J = 9.4, 5.4), 5.24-5.13 (m, 2H), 4.54 (d, 1H, J = 5.4), 4.35 (dd, 1H, J = 6.9, 1.6), 3.20 (s, 3H), 3.18 (s, 3H), 3.11 (s, 6H), 3.05 (s, 3H), 3.04 (s, 3H), 2.72 (m, 2H), 2.61 (m, 4H), 2.42 (m, 2H), 2.26-2.12 (m, 4H), 0.92 (s, 9H), 0.87 (s, 9H), 0.19 (s, 3H), 0.18 (s, 3H), 0.15 (s, 3H), 0.08 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 158.06, 157.99, 156.93, 150.34, 136.75, 136.43, 121.20, 89.19, 88.54, 86.97, 86.46, 83.87, 79.69, 79.22, 47.39, 47.30, 46.53, 46.39, 41.70, 38.59, 38.00, 37.84, 35.50, 25.83, 25.80, 18.04, -2.46, -2.48.

(3'S, 6'R)- N2-[N,N-Dimethylformamidino]-9-{6'-O-acetyl-3'-O-[(*tert*-butyl)-dimethylsilyl]-2'-deoxy-3',5'-ethano-α- and -β-D-ribofuranosyl} guanine **43a/b** A solution containing **42a/b** (620 mg, 1.15 mmol) and CsOAc (3.0 g, 15.9 mmol) in DMSO (16 ml) was heated to 85°C and stirred for 16 h. After cooling to r.t. the mixture was diluted with ethyl acetate and washed with sat. NaHCO₃. The combined organic layers were washed with H₂O and dried over MgSO₄. By FC purification (5% methanol in DCM) **43a/b** (491 mg, 0.97 mmol, 85%) was obtained in an anomeric ratio of α/β=2:1 as a white foam. ¹H-NMR showed still a considerable amount of DMSO. R_f 0.5 (10% methanol in DCM), HR-MS (ESI⁺, EtOAc) for C₂₃H₃₆N₆O₅Si. Calc: 505.2589, found: 505.2582 (M + H⁺). ¹H NMR (400 MHz, CDCl₃) δ 9.72 (br, 2H), 8.60 (s, 1H), 8.58 (s, 1H), 7.95 (s, 1H), 7.89 (s, 1H), 6.32 (m, 1H), 6.22 (m, 1H), 5.34 (m, 2H), 4.59 (m, 1H), 4.36 (dd, 1H, J = 6.9, 1.3), 3.17 (m, 6H), 3.10 (m, 6H), 2.70-2.53 (m, 4H), 2.41-2.28 (m, 6H), 2.16 (m, 2H), 2.06 (s, 3H), 2.05 (s, 3H), 0.90 (s, 9H), 0.87 (s, 9H), 0.14 (m, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 170.49, 158.39, 158.13, 157.17, 156.95, 150.16, 136.83, 135.83, 132.06, 120.35, 95.82, 91.14, 91.03, 89.43, 89.36, 84.92, 83.83, 76.72, 76.30, 48.04, 46.85, 46.22, 45.88, 41.57, 37.76, 37.59, 35.40, 25.85, 25.80, 25.74, 21.52, 21.40, 17.99, -2.56, -2.63, -2.73.

(3'S, 6'R)- 9-{3'-O-[(*tert*-butyl)-dimethylsilyl]-2'-deoxy-3',5'-ethano-α- and -β-D-ribofuranosyl} guanine (**44a**, **44b**) The anomeric mixture **43a/b** (512 mg, 1.0 mmol) was dissolved in 1 M KOH in 5:3 methanol/H₂O (12 ml). The solution was stirred for 6 h at 60°C and quenched by the addition of ammonium chloride. The solvents were then evaporated and the remains absorbed on silica gel. Purification by FC (5% methanol in DCM) yielded the anomers **44b** (170 mg, 0.42 mmol, 42%) and **44a** (78 mg, 0.2 mmol, 20%) as white solids. Analytical data for **44a**: R_f 0.27 (10% methanol in DCM), HR-MS (ESI⁺, MeOH) for C₁₈H₂₉N₅O₄Si. Calc: 408.2062, found 408.2056 (M + H⁺). ¹H NMR (400 MHz, MeOD) δ 7.96 (s, 1H), 6.19 (dd, 1H, J = 9.5, 5.7), 4.48 (m, 1H), 4.34 (dd, 1H, J = 7.0, 1.7), 2.93 (dd, 1H, J = 13.4, 9.6), 2.59 (dd, 1H, J = 13.4, 5.7), 2.26 (m, 2H), 2.08 (dd, 1H, J = 13.7, 5.4), 1.95 (m, 1H), 0.93 (s, 9H), 0.19 (s, 3H), 0.17 (s, 3H). ¹³C NMR (101 MHz, MeOD) δ 159.29, 155.44, 152.66, 137.90, 117.66, 93.15, 91.18, 85.41, 74.81, 49.30, 41.34, 26.18, 18.69, -2.53, -2.59. Analytical data for **44b**: TLC R_f 0.27 (10% methanol in DCM), HR-MS (ESI⁺, MeOH) for C₁₈H₂₉N₅O₄Si. Calc: 408.2062, found 408.2057 (M + H⁺). ¹H NMR (400 MHz, MeOD) δ 7.89 (s, 1H), 6.26 (dd, 1H, J = 6.7, 3.0), 4.66 (dd, 1H, J = 7.0, 2.0), 4.45 (m, 1H), 2.95 (dd, 1H, J = 13.9, 6.7), 2.75 (dd, 1H, J = 13.9, 3.0), 2.31 (m, 1H), 2.14 (m, 2H), 1.84 (m, 1H), 0.78 (s, 9H), 0.11 (s, 3H), -0.02 (s, 3H). ¹³C NMR (101 MHz, MeOD) δ 159.33, 155.17, 152.30, 135.17, 118.09, 94.21, 91.23, 88.09, 74.20, 49.66, 48.90, 41.35, 26.06, 18.57, -2.56, -2.89.

(3'S, 6'R)- N2-[N,N-Dimethylformamidino]-9-{3'-O-[(*tert*-butyl)-dimethylsilyl]-2'-deoxy-3',5'-ethano-β-D-ribofuranosyl} guanine **45b** The nucleoside **44b** (170 mg, 0.41 mmol) was dissolved in DMF (4.5 ml) and N,N-dimethylformamid dimethyl acetate (0.11 ml, 0.82 mmol) was added. The solution was stirred for 3h at 55°C. The DMF was then evaporated by Kugelrohr distillation and the crude product purified by FC (10% methanol in DCM). Compound **45b** (122 mg, 0.26 mmol, 64%) was obtained as a white foam. R_f 0.3 (10% methanol in DCM), HR-MS (ESI⁺, MeCN) for C₃₁H₅₄N₆O₄Si. Calc: 463.2484, found 463.2475 (M + H⁺). ¹H NMR (400 MHz, CDCl₃) δ 9.13 (s, 1H), 8.68 (s, 1H), 7.87 (s, 1H), 6.04 (dd, 1H, J = 10.0, 5.5), 4.53 (m, 1H), 4.35 (d, 1H, J = 6.3), 3.22 (dd, 1H, J = 13.4, 10.1), 3.17 (s, 3H), 3.07 (s, 3H), 2.53 (dd, 1H, J = 13.4, 5.5), 2.40 (m, 1H), 2.18 (m, 1H), 2.10 (m, 1H), 2.01 (m, 1H), 0.90 (m, 9H), 0.15 (s, 3H), 0.13 (m, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 81.93, 80.54, 79.99, 72.95, 60.80, 44.42, 15.14, 12.56, 7.82, 0.20, -1.84, -27.06, -29.22, -35.90, -36.81, -42.05, -51.34, -59.19, -79.57, -79.66.

(3'S,6'R)- N2-[N,N-Dimethylformamidino]-9-{5'-O-[4,4'-(dimethoxytriphenyl)methyl]-3'-O-[(*tert*-butyl)-dimethylsilyl]-2'-deoxy-3',5'-ethano-β-D-ribofuranosyl} guanine **46b** To a solution of nucleoside **45b** (70 mg, 0.15 mmol) in pyridine (0.7 ml) was added DMT-Cl (154 mg 0.45 mmol) in three portions and it was stirred for 24 h at r.t. The solution was then diluted with ethyl acetate, washed with sat. NaHCO₃ and dried over MgSO₄. Purification by FC (5% methanol in DCM) yielded the nucleoside **46b** (108 mg, 0.14 mmol, 94%) as a white foam. R_f 0.66 (10% methanol in DCM), HR-MS (ESI⁺, MeCN) for C₄₂H₅₂N₆O₆Si. Calc: 765.3790, found 765.3779 (M + H⁺). ¹H NMR (300 MHz, CDCl₃) δ 8.94 (br, 1H), 8.61 (s, 1H), 7.88 (m, 1H), 7.47 (m, 2H), 7.36 (m, 4H), 7.30 (m, 1H), 7.20 (m, 1H), 6.83 (m, 4H), 6.19 (dd, 1H, J = 9.6, 5.1), 4.27 (m, 1H), 4.12 (dd, 1H, J = 7.5, 3.9), 3.79 (s, 6H), 3.13 (s, 3H), 3.10 (s, 3H), 2.73 (dd, 1H, J = 13.0, 9.6), 2.42 (dd, 1H, J = 13.0, 5.1), 1.98 (m, 1H), 1.68 (m, 1H), 1.60 (m, 2H), 0.83 (s, 9H), 0.04 (s, 3H), -0.04 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 158.86, 158.29, 157.96,

156.81, 150.17, 145.69, 136.96, 136.21, 130.28, 128.28, 128.22, 127.11, 113.55, 90.76, 88.62, 87.44, 84.73, 75.66, 55.47, 46.96, 45.56, 41.51, 39.70, 35.37, 25.88, 18.02, -2.63.

(3'S, 6'R)-N2-[N,N-Dimethylformamidino]-9-[6'-O-[4,4'-(dimethoxytriphenyl)methyl]-2'-deoxy-3',5'-ethano-β-D-ribofuranosyl] guanine **47b** Nucleoside **46b** (74 mg, 0.1 mmol) was dissolved in THF (2.2 ml) and TBAF (1 M in THF, 0.1 ml, 0.1 mmol) was added. The clear solution was stirred for 5 h at r.t. and then quenched by the addition of silica. Purification by FC (5% methanol in DCM) yielded **47b** (44 mg, 70 %) as a white foam. R_f 0.4 (10% methanol in DCM), HR-MS (ESI⁺, MeCN, 0.1% HFO) for C₃₆H₃₈N₆O₆, Calc. 651.2926, found 651.2925 (M + H⁺) ¹H NMR (400 MHz, MeOD) δ 8.68 (s, 1H), 7.97 (s, 1H), 7.46 (m, 2H), 7.34 (m, 4H), 7.27 (m, 2H), 7.21 (m, 1H), 6.84 (m, 4H), 6.24 (dd, 1H, *J* = 9.4, 5.4), 4.33 (m, 1H), 4.08 (dd, 1H, *J* = 7.4, 3.4), 3.78 (s, 6H), 3.16 (s, 3H), 3.12 (s, 3H), 2.91 (dd, 1H, *J* = 13.1, 9.5), 2.49 (dd, 1H, *J* = 13.2, 5.4), 1.95 (m, 1H), 1.82 (m, 1H), 1.67 (dd, 1H, *J* = 14.0, 6.1), 1.57 (m, 1H). ¹³C NMR (101 MHz, MeOD) δ 160.25, 159.82, 159.17, 151.84, 147.10, 138.25, 138.09, 138.06, 131.32, 129.33, 128.92, 127.86, 120.65, 114.27, 90.89, 88.62, 87.54, 85.98, 77.02, 55.73, 47.44, 46.93, 41.52, 40.74, 35.33.

(3'S,6'R)-N2-[N,N-Dimethylformamidino]-9-[3'-O-[(2-cyanoethoxy)(diisopropylamino)phosphino]-6'-O-[4,4'-(dimethoxytriphenyl)methyl]-3'-O-[(tert-butyl)-dimethylsilyl]-2'-deoxy-3',5'-ethano-β-D-ribofuranosyl] guanine **48b** To a solution of **47b** (44 mg, 0.07 mmol) in MeCN (1 ml) was added Hünig's base (0.06 ml, 0.34 mmol) and Cep-Cl (0.04 ml, 0.2 mmol). The mixture was stirred at r.t. for 1 h then diluted with ethyl acetate and washed with sat. NaHCO₃. Purification by FC (3% methanol in DCM) yielded the desired phosphoramidite **48b** (50 mg, 0.06 mmol, 88%) as a white foam. R_f 0.7 (10% methanol in DCM), HR-MS (ESI⁺, MeCN) for C₄₅H₅₅N₈O₇P. Calc. 851.4010, found 851.4009 (M + H⁺), ¹H NMR (400 MHz, CDCl₃) δ 8.95 (br, 1H), 8.60 (m, 1H), 7.85 (m, 1H), 7.45 (m, 2H), 7.35 (m, 4H), 7.28 (m, 2H), 7.21 (m, 1H), 6.83 (m, 4H), 6.22 (m, 1H), 4.32 (m, 2H), 3.79 (m, 6H), 3.77-3.54 (m, 4H), 3.13 (s, 3H), 3.09 (m, 3H), 2.84 (m, 2H), 2.57 (t, 1H, *J* = 6.3), 2.51 (t, 1H, *J* = 6.3), 2.09 (m, 1H), 1.86 (m, 2H), 1.60 (m, 1H), 1.15 (m, 9H), 1.09 (d, 3H, *J* = 6.8). ¹³C NMR (101 MHz, CDCl₃) δ 158.80, 158.33, 158.00, 156.94, 156.88, 150.38, 150.30, 145.66, 136.87, 136.83, 136.38, 130.30, 130.25, 128.24, 127.08, 120.90, 117.75, 113.53, 90.91, 90.82, 90.76, 89.12, 87.55, 87.52, 84.33, 75.62, 75.51, 58.20, 58.02, 57.92, 55.46, 44.92, 44.60, 43.59, 43.47, 41.50, 39.41, 35.36, 29.89, 24.75, 24.50, 20.53. ³¹P NMR (122 MHz, CDCl₃) δ 141.88.

RNase H activity: A 0.2 μM solution of the oligonucleotide **S10** and of the corresponding DNA and RNA strands was solved in a buffer system containing 75 mM KCl, 50 mM Tris-HCl, 3mM MgCl₂ and 10 mM dithiothreitol and was then hybridized with 0.1 μM of the ³²P labelled complementary RNA strand to give a total volume of 60 μl. After heating to 80°C the solution was incubated for 15 min. at 37°C. 2.5 U of the enzyme were then added and the mixture was kept at 25°C. Aliquots were taken at 5, 45, 120 and 300 min. and were quenched by the addition of a loading buffer (100% formamid, bromophenol blue and xylencyanol). The samples were stored at 4°C over night, analysed on a 20% denaturing polyacrylamide gel and the bands visualized by autoradiography.

Serum stability: 202 μl of the sequence **S10** and 108 μl of the corresponding DNA sequence (~30 μg each) were speed vac dried. The remains were taken up in 386 μl DMEM/F12 (Dulbecco's Modified Eagle Medium), incubated at 37°C and 40 μl of FBS was added to give a total concentration of 10% serum. Aliquots of 84 μl were taken after 0, 0.5, 2, 6.5 and 21 h and quenched by the addition of 80 μl 9 M urea in 2x TBE buffer. To the solutions were then added 60 μl of H₂O and they were precipitated in 25 μl 3 M NaOAc and 1 ml cold ethanol. After 1 h at -80°C the tubes were centrifuged for 1 h at 2 °C. The remains were taken up in 15 μl loading buffer (formamide/TBE 9:1) and separated on a 20% polyacrylamide gel. In order to visualize the bands the gel was stained with *stains-all*.

iso-bicyclo oligonucleotide synthesis: The chemical synthesis of oligonucleotides was performed on the 1.3μmol scale on a *Pharmacia LKB Gene Assembler Special DNA-synthesizer* using standard phosphoramidite chemistry. The phosphoramidite building blocks of the natural nucleosides and the nucleosides bound to CPG-solid support were purchased from *Glen Research*. Universal solid support was purchased from *Glen Research* or *CTGen*. Natural oligonucleotides were purchased from *Microsynth*. Solvents and reagents used for the synthesis were prepared according to the manufacturer's indications. 5-(ethylthio)-1H-tetrazole (ETT) was used as activator and dichloroacetic acid in dichloroethane was used for the detritylation step. The concentrations of the phosphoramidite solutions were 0.1 M. The coupling times for natural phosphoramidites were 1.5 min and for the modified phosphoramidite 9 min. The oligonucleotides **S1-S4** were cleaved from the resin and deprotected in 33% NH₃ solution at 55°C overnight. Also the fully modified sequences **S6, S7, S10, S11** were cleaved and deprotected in 33% NH₃ but at 70°C overnight. After evaporation the crude samples were filtered, taken up in water and purified by reversed phase (Source 15 RPC ST 100/4.6 Polystyrene-15 column from Pharmacia Biotech) or DEAE-HPLC (DNAPac-200 4 x 250 mm column with pre-column both from *Dionex*). All samples were then desalted over a Sep-Pak[®] C-18 cartridge (*Waters*) according to the manufacturer's protocol. The integrity of all oligonucleotides was confirmed by ESI-

MS spectrometry. Concentrations of the oligonucleotide solutions were determined by UV absorption at 260 nm. The extinction coefficients ε of the oligonucleotides were supposed to be identical to natural oligonucleotides and were calculated using the oligocalculator (www.ambion.com).

UV/Vis Spectroscopy: Thermal denaturation experiments were measured on a *Cary 100 Bio, UV-Visible Spectrophotometer*. The samples were measured at 260 nm and the heating rate was set to 0.5°C/min. The first derivatives of the curves were calculated with the *Origin Pro 8* program. To avoid evaporation of the solution, a layer of dimethylpolysiloxane was added over the samples within the cell. The OD values of the oligonucleotides were measured with a *NanoDrop ND-1000 Spectrophotometer* at 260 nm.

Circular dichroism spectroscopy (CD): Circular dichroism spectra were recorded on a Jasco J-715 spectropolarimeter equipped with a *Jasco PFO-350S temperature controller*. The temperature was measured from the heating block. The graphs were subsequently smoothed with a noise filter. The phosphate buffer was used as blank. Spectra are given in mdeg from 210 to 320 nm.

Molecular modeling: Molecular modeling were carried out with the Amber force field as incorporated in the software package *HyperChem™ Release 8.0.4* for Windows of Hypercube, Inc. Only original Amber parameters were used and no explicit water or counterions were included.

Acknowledgements

We thank the Swiss National Science Foundation and the Association Monégasque contre les Myopathies (AMM) for financial support of this project.

- [1] J. Kurreck, *Angew. Chem. Int. Ed.* **2009**, 48, 1378-1398.
- [2] C. F. Bennett, E. E. Swayze, *Annu. Rev. Pharmacol. Toxicol.* **2010**, 50, 259-293.
- [3] The ENCODE project consortium, *Nature* **2012**, 489, 57-74.
- [4] a) J. C. van Deutekom, A. A. Janson, I. B. Ginjaar, W. S. Frankhuizen, A. Aartsma-Rus, M. Bremmer-Bout, J. T. den Dunnen, K. Koop, A. J. van der Kooi, N. M. Goemans, S. J. de Kimpe, P. F. Ekhardt, E. H. Venneker, G. J. Platenburg, J. J. Verschuuren, G. J. van Ommen, *N. Engl. J. Med.* **2007**, 357, 2677-2686; b) M. Manoharan, *Biochim. Biophys. Acta* **1999**, 1489, 117-130.
- [5] H. M. Moulton, J. D. Moulton, *Biochim. Biophys. Acta* **2010**, 1798, 2296-2303.
- [6] M. Egholm, O. Buchardt, L. Christensen, C. Behrens, S. M. Freier, D. A. Driver, R. H. Berg, S. K. Kim, B. Norden, P. E. Nielsen, *Nature* **1993**, 365, 566-568.
- [7] a) S. K. Singh, P. Nielsen, A. A. Koshkin, J. Wengel, *Chem. Comm.* **1998**, 455-456; b) S. Obika, D. Nanbu, Y. Hari, J. I. Andoh, K. I. Morio, T. Doi, T. Imanishi, *Tetrahedron Lett.* **1998**, 39, 5401-5404.
- [8] a) M. Bolli, H. U. Trafelet, C. Leumann, *Nucleic Acids Research* **1996**, 24, 4660-4667; b) M. Tarköy, M. Bolli, C. Leumann, *Helv. Chim. Acta* **1994**, 77, 716-744; c) M. Tarköy, C. Leumann, *Angew. Chem. Intl. Ed.* **1993**, 32, 1432-1434; d) P. Silhár, C. J. Leumann, *Bioorg. Med. Chem.* **2010**, 18, 7786-7793.
- [9] a) D. Renneberg, C. Leumann, *J. Am. Chem. Soc.* **2002**, 124, 5993-6002; b) S. Murray, D. Ittig, E. Koller, A. Berdeja, A. Chappell, T. P. Prakash, M. Norrbom, E. E. Swayze, C. J. Leumann, P. P. Seth, *Nucleic Acids Res.* **2012**, 40, 6135-6143; c) J. Lietard, C. J. Leumann, *J. Org. Chem.* **2012**, 77, 4566-4577.
- [10] R. Steffens, C. Leumann, *Helv. Chim. Acta* **1997**, 80, 2426-2439.
- [11] R. Meier, S. Grünschow, C. J. Leumann, *Helv. Chim. Acta* **1999**, 82, 1813-1828.
- [12] X.-F. Zhu, H. J. Williams, A. I. Scott, *J. Chem. Soc., Perkin Trans 1* **2000**, 2305-2306.
- [13] J. H. van de Sande, N. B. Ramsing, M. W. Germann, W. Elhorst, B. W. Kalisch, E. von Kitzing, R. T. Pon, R. C. Clegg, T. M. Jovin, *Science* **1988**, 551-557.
- [14] C. Hendrix, H. Rosemeyer, I. Verheggen, F. Seela, A. Van Aerschot, P. Herdewijn, *Chem. Eur. J.* **1997**, 3, 110-120.
- [15] a) A. K. Shchyolkina, Y. P. Lysov, I. A. Il'ichove, A. A. Chernyi, Y. B. Golova, B. K. Chernov, B. P. Gottikh, V. L. Florentiev, *FEBS Lett.* **1989**, 244, 39-42; b) A. K. Shchyolkina, O. F. Borisova, M. A. Livshits, G. E. Pozmogova, B. K. Chernov, R. Klement, T. M. Jovin, *Biochemistry* **2000**, 10034-10044.
- [16] M. Petersheim, D. H. Turner, *Biochemistry* **1983**, 22, 256-263.
- [17] G. S. Manning, *Acc. Chem. Res.* **1979**, 11, 443-449.

-
- [18] *Circular Dichroism: Principles and Applications*, second ed., John Wiley & Sons, **2002**.
- [19] L. Bellon, J.-L. Barascut, G. Maury, G. Divita, R. Goody, J.-L. Imbach, *Nucleic Acids Res.* **1993**, *21*, 1587-1593.
- [20] J. Wang, B. Verbeure, I. Luyten, E. Lesclerier, M. Froeyen, C. Hendrix, H. Rosemeyer, F. Seela, A. van Aerschot, P. Herdewijn, *J. Am. Chem. Soc.* **2000**, *122*, 8595-8602.
- [21] J. Kypr, I. Kejnovska, D. Renciuik, M. Vorlickova, *Nucleic Acids Res.* **2009**, *37*, 1713-1725.
- [22] M. Vorlickova, J. Kypr, V. Sklenar, A. Klug, *J. Mol. Biol.* **1983**, *166*, 85-92.
- [23] N. G. A. Abrescia, A. Thompson, T. Huynh-Dinh, J. A. Subirana, *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 2806-2811.
- [24] a) A. K. Shchvolkina, O. F. Borisova, M. A. Livshits, T. M. Jovin, *J. Mol. Biol.* **2003**, *37*, 223-231; b) C. Otto, G. A. Thomas, T. M. Jovin, W. L. Peticolas, *Biochemistry* **1991**, *30*, 3062-3069.
- [25] a) W. F. Lima, S. T. Crooke, *Biochemistry* **1997**, *36*, 390-398; b) W. F. Lima, V. Mohan, *J. Biol. Chem.* **1997**, *272*, 18191-18199.
-
- [26] E. Zamaratski, P. I. Pradeepkumar, J. Chattopadhyaya, *J. Biochem. Biophys. Methods* **2001**, *48*, 189-208.
- [27] D. Yu, R. P. Iyer, D. R. Shaw, J. Lisiewicz, Y. Li, Z. Jiang, A. Roskey, S. Agrawal, *Bioorg. Med. Chem.* **1996**, *4*, 1685-1692.
- [28] C. Wahlestedt, P. Salmi, L. Good, J. Kela, T. Johnsson, T. Hökfelt, C. Broberger, F. Porreca, J. Lai, K. Ren, M. Ossipov, A. Koshkin, N. Jakobsen, J. Skouv, H. Oerum, M. H. Jacobsen, J. Wengel, *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 5633-5638.

Received: ((will be filled in by the editorial staff))

Revised: ((will be filled in by the editorial staff))

Published online: ((will be filled in by the editorial staff))

Entry for the Table of Contents

A twist to DNA structure

Anna-Barbara Gerber, Christian J.
Leumann * Page – Page

Synthesis and properties of iso-bicyclo DNA

Moving the phosphodiester backbone from the natural C(5') position to the C(6') position which is only available on the bicyclo-DNA skeleton, leads to iso-bicyclo-DNA. Iso-bc-DNA forms stable

duplexes with DNA and discriminates RNA as complement. In addition it forms very stable antiparallel self-duplexes with a structure that is different from A-, B- or Z-DNA.